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Abstract
Eicosanoids are major players in the pathogenesis of several common diseases, with either overproduction or
imbalance (e.g. between thromboxanes and prostacyclins) often leading to worsening of disease symptoms. Both
the total rate of eicosanoid production and the balance between eicosanoids with opposite effects are strongly
dependent on dietary factors, such as the daily intakes of various eicosanoid precursor fatty acids, and also on the
intakes of several antioxidant nutrients including selenium and sulphur amino acids. Even though the underlying
biochemical mechanisms have been thoroughly studied for more than 30 years, neither the agricultural sector nor
medical practitioners have shown much interest in making practical use of the abundant high-quality research data
now available. In this article, we discuss some specific examples of the interactions between diet and drugs in the
pathogenesis and therapy of various common diseases. We also discuss, using common pain conditions and
cancer as specific examples, how a better integration between agricultural science, nutrition and pharmacology
could lead to improved treatment for important diseases (with improved overall therapeutic effect at the same
time as negative side effects and therapy costs can be strongly reduced). It is shown how an unnaturally high
omega-6/omega-3 fatty acid concentration ratio in meat, offal and eggs (because the omega-6/omega-3 ratio of
the animal diet is unnaturally high) directly leads to exacerbation of pain conditions, cardiovascular disease and
probably most cancers. It should be technologically easy and fairly inexpensive to produce poultry and pork meat
with much more long-chain omega-3 fatty acids and less arachidonic acid than now, at the same time as they
could also have a similar selenium concentration as is common in marine fish. The health economic benefits of
such products for society as a whole must be expected vastly to outweigh the direct costs for the farming sector.
Background
The world is faced with unprecedented challenges in the
environmental sector, especially as a consequence of
large anthropogenic emissions of greenhouse gases
(including methane and N2O from agriculture), but also
because of unchecked deforestation and soil erosion
affecting large geographical areas. On top of this, we have
serious pollution problems that may not only threaten
non-human species (such as the polar bear), but also can
represent a serious genetic hazard to Homo sapiens him-
self, since many of the pollutants concerned are either
highly mutagenic or weaken important antimutagenic
defense mechanisms, and they interact with several other
chemical mutagens (e.g. from tobacco, alcohol and muta-
genic drugs) associated with our modern lifestyles.
The most serious immediate threat to us might concei-
vably come from various positive feedback regulatory
mechanisms inherent in the global climatic system, lead-
ing to the possibility of a sudden, major change in global
temperature and/or in the geographical distribution of
arid and humid zones. It is known that such sudden
changes of the global climate, as exemplified by the end
of the Younger Dryas [1], have occurred repeatedly dur-
ing the fairly recent geological past [2], most recently
about 4.2 thousand years ago when the Akkadian Empire
[3] and the Egyptian Old Kingdom [4] both collapsed.
During the last event, the change of global temperature
was much more modest than had been the case at the
end of the Younger Dryas. But there was a major change
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Africa [3-5], and the Sahara region was permanently
changed into a desert [6].
The world is also faced with soaring food prices [7] and
very serious challenges in the medical sector, not only in
the poor countries [8], but also as a consequence of those
changes that are taking place in the age structure of the
populations of many industrial countries, at the same
time as a number of not acutely lethal non-infectious dis-
eases, such as diabetes type 2 and asthma, have become
much more prevalent than they were before. The health
sector and the environmental sector are, however, com-
peting with each other for the same limited economic
and manpower resources, and it is difficult to see how
this situation will change in the foreseeable future. The
question may thus be raised, whether it will be economic-
ally and politically possible, even for the most affluent
countries in North America and Europe, to solve both
challenges simultaneously. And who should be left back
on the sinking ship, the Alzheimer patients or the global
environment, if there is not enough room for both in the
lifeboats?
This means that it may be necessary also for the health
sector, including the worldwide community of medical
scientists, to take its part of the burden, if it shall be pos-
sible to avert worldwide economic, social and political
collapse as a result of global climatic catastrophe and
attendant famine on a scale (as measured by the total
number of victims) that might turn out to be unprece-
dented in the history of our species. There may not be
enough resources available to avert total environmental
and genetic disaster unless the health sector worldwide
can be made vastly more cost-efficient than it is today.
But doing so is not something that can be achieved by
medical scientists and other health professionals acting
alone (e.g. by finding new and better drugs), since better
prophylaxis of several important diseases will not be pos-
sible unless the nutritional quality of the human diet can
be made much better than is often the case today. This
applies not only to poor countries, but to many of the
rich ones as well. It is therefore a great challenge to agri-
cultural scientists, food scientists and nutrition scientists
to develop methods and strategies by which agriculture
indirectly may make it easier for the world to confront
the problems in the environmental sector - by providing
foods with better composition and thus reducing the
costs needed for health care.
This challenge relates equally to the animal food and to
the plant food sectors, with their associated industries as
well as to agriculture itself. It will be up to the politicians
and international and state regulatory agencies to imple-
ment the necessary changes, in particular by imposing
new regulatory standards for the composition of com-
monly consumed foods (like poultry meat, pork meat and
eggs). In this article, we will not discuss the issues of local
and global resource constraints, skewed global distribu-
tion of limited resources, nor the adverse ecological side
effects, like deforestation and emission of greenhouse
gases, that attend food production in both rich and poor
countries. We will limit our attention to the composition
of some of the quantitatively most important animal
foods, viz. poultry meat, pork and eggs. It will be shown
how improving the composition of these foods may lead
to better prophylaxis of several important diseases. Hope-
fully this can also make a significant contribution to
improved treatment of some of the diseases concerned
(with an improved ratio between therapeutic effects and
negative side effects), while perhaps also making therapy
economically more cost-effective than now. Examples,
based on our own research, show how it is practically
feasible (and not too expensive) to obtain such changes
in the composition of agricultural products that for medi-
cal reasons are needed. But there are also other methods
that may be used to obtain similar results. However, we
consider it to lie beyond the scope of the current discus-
son to survey all of the methods that in theory might
be used and to compare them as regards their practical
feasibility, or from the point of view of agricultural
economics.
Animal products and health: selenium-rich and
long-chain omega-3-fatty acid-rich fish versus
arachidonic acid-rich meat
The market demand for foods with a nutrient composi-
tion adjusted to optimize human health and life expec-
tancy is growing. Such foods are often referred to as
functional foods. Many foods have so many beneficial
health effects even without any modification during pro-
duction or processing that they might well be referred
to as natural functional foods. The composition of cer-
tain other foods has been so much modified as a result
of industrial methods of food production or processing
that they well might deserve to be referred to as ‘anti-
functional foods’, since their negative health effects may
outweigh the positive ones. Some foods can not be char-
acterised either as uniquely functional or antifunctional
because their positive health effects may be dominating
only for certain groups of consumers (depending on
their specific dietary requirements, the nature of their
most important disease problems and the composition
of the rest of their diet); the negative health effects of
the same type of food may be the dominating ones for
other consumer groups.
Sea fish products can be regarded as natural func-
tional foods; their protecti v ee f f e c t sc a nb ee x p l a i n e d
partly by high natural concentrations of long-chain
omega-3 fatty acids (especially in fatty fish), taurine
[9-12] and selenium. Meat is usually regarded as less
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diseases and cancer. Chicken meat, nevertheless, is com-
monly regarded by both health professionals and the
general public as a healthful type of meat; it is well-
liked, and the consumption is increasing [13]. Chicken
meat is lean, protein-rich and a good source of impor-
tant micronutrients, such as zinc and vitamin B12,a n d
conditionally essential nutrients, such as nucleotides
(mainly in the form of RNA and DNA) and carnitine.
Chicken meals are often preferred to a fish dinner, even
in such cases when the consumer knows that fish is
more healthful regarding both omega-3 fatty acids and
selenium. However, the concentration of selenium (Se)
in chicken breast meat in Scandinavia is only about
0.01 mg/100 g [14,15], while fish fillet contains about
3 to 4 times as much [14,16].
In chicken thigh meat, the total amount of the very
long-chain omega-3 fatty acids eicosapentaenoic acid
(EPA), docosapentaenoic acid (DPA) and docosahexae-
noic acid (DHA), as given by the Danish food composi-
tion table, is only about 0.06 g/100 g, while in cod it is
0.26 g/100 g and in fatty fish such as salmon it is about
2.8 g/100 g [14]. The concentration of arachidonic acid
(AA) in chicken is 0.09 g/100 g, in cod 0.02 g/100 g and
in salmon 0.09 g/100 g [16]. Thus the ratio between AA
and the sum of EPA+DPA+DHA is 10-40 times higher
in chicken than in fish. These figures show that nowa-
days fish fillet is not only a better source of Se, but also
am u c hb e t t e rs o u r c ef o romega-3 fatty acids than
chicken meat, and that fish gives a much lower relative
load of AA.
The fatty acid composition and Se concentration in
chicken meat depend largely on the composition of the
diet fed to the birds. Feed composition affects the fatty
acid composition of the product [17], and it has earlier
been shown that feeding poultry with omega-3 fatty
acids from rapeseed oil and linseed oil improved the
ratio between omega-6 and omega-3 fatty acids and
increased the concentrations of alpha-linolenic acid
(ALA), EPA, DPA and DHA in broiler thigh muscle
[18]. Furthermore it is known that dietary supplements
of Se-enriched yeast increase the Se concentration of
the chicken meat [19] and other animal products [20].
Commercial chicken feed is cereal-based (wheat, barley
or corn), and the added fat is mostly rendered fat and
vegetable oils, giving a diet with a high ratio of omega-6
to omega-3 fatty acids. The diet eaten by poultry in
their natural habitats consists of seeds, plants, insects
etc., providing plenty of minerals, micronutrients and
plant antioxidants and a much higher proportion of
omega-3 fatty acids compared to omega-6 fatty acids
than in those feed mixtures that are now commonly
used in commercial poultry production.
What is the role of endogenous synthesis of long-chain
polyunsaturated fatty acids in humans, compared with
intake from the diet?
The human organism can, like other mammals, use fatty
acyl elongases and desaturases to convert the 18C
PUFAs linoleic acid (LA), ALA and gamma-linolenic
acid (GLA) into long-chain PUFAs. But attempts to
measure the rate of endogenous synthesis of AA, EPA
a n dD H Ai nh u m a n s ,c o m p a r e dt ot h em a g n i t u d eo f
ordinary dietary intakes of long-chain PUFAs (in popu-
lations with a mixed diet), have given discrepant results
with most studies [21-23] showing poor and some extre-
mely poor [24] conversion of 18C PUFAs into long-
chain PUFAs: < 5-10% for EPA and 2-5% for DHA [22].
It is difficult to understand, however, how women who
are lactovegetarians or vegans can give birth to babies
with normal brains if the endogenous capacity of DHA
synthesis from ALA in humans is not larger than some
of the experimental studies (especially from North
America) have shown. There are several hundred mil-
lion poor people worldwide (probably more than 1 bil-
lion altogether) who for purely economic reasons can
not afford to eat more than minuscule quantities of ani-
mal foods. It may be legitimate to ask the question, how
it is possible for the children of all these people to grow
up without serious learning problems and intellectual
deficits due to inadequate DHA supply for the growing
brain, unless the human capacity to make DHA from
ALA is better (perhaps locally in the brain, if not neces-
sarily at a systemic level outside the central nervous sys-
tem) than some of the best studies until now do
indicate. It is evident that the health of several children
must be damaged owing to several other forms of mal-
nutrition that have a large global prevalence and also
affect brain development, like zinc [25,26], iodine
[27,28], iron [29,30], folate [31] and vitamin B12 [32]
deficiencies. But we might expect the situation world-
wide to be even worse if the effect of widespread DHA
deficiency on brain development comes in addition to
all the other deficiencies that we know exist.
In a traditional Mediterranean diet with high intake of
olive oil, much of the total intakes both of LA and ALA
would be expected to come from olive oil, which has an
LA/ALA concentration ratio that for genetic reasons is
variable, but often may be around 10/1 [33,34]. A study
of the fatty acid composition of human blood samples
from the population in Crete showed, however, that
plasma lipoprotein cholesteryl ester contained 31.0 +/-
2.7% oleic acid, 41.9 +/- 3.7% LA and only 0.9 +/- 0.5%
ALA [35]. Unless there is a highly preferential incor-
poration of LA instead of ALA into plasma lipoprotein
cholesteryl esters (which can not be a priori excluded),
these figures suggest faster metabolic degradation of
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tor of 4. This could be either because of faster beta-
oxidation or peroxisomal oxidation of ALA, compared
to LA, or because of faster conversion of ALA into
long-chain PUFAs.
The latter hypothesis would help to solve the paradox
of how it may be possible for the children of vegan and
lactovegetarian women to grow up without serious cog-
nitive deficits resulting from inadequate DHA supply to
their growing brain. If correct, it also suggests that
humans may have high capacity to convert ALA into
long-chain omega-3 PUFAs, even in situations where the
intake of long-chain PUFAs from animal foods is fairly
high. If this explanation for the observations from Crete
is correct, it implies that at least one of the elongases or
desaturases must have high substrate specificity, with
t h er a t eo fomega-3 fatty acid conversion being much
higher than for its omega-6 fatty acid analogue. This
would not appear unreasonable from the point of view
of evolutionary ecology, given the large size of the
human brain and the very high normal concentration of
DHA in the membrane lipids of vertebrate brains.
The explanation for the highly divergent observations
concerning the possible capacity of humans to convert
18C PUFAs into long-chain ones is not well understood.
Some causes of variations in the capacity for converting
ALA into DHA are known either from studies in ani-
mals or humans (or both): there is a gender difference
with adult female rats [36,37] and adult female humans
[36] both having better capacity to convert ALA into
DHA compared to adult males. And it has been found
in rats that vitamin A deficiency is associated with
impairment of this conversion in animals fed an ALA-
poor diet [38], while the opposite effect of vitamin A
deficiency was observed in the liver when the intake of
ALA was high [39]. However, neither of these factors
can explain why ALA conversion into DHA might be
poorer in Canada [24] than in Crete.
It is not unreasonable that part of the explanation for
individual or geographic differences in the capacity to
convert 18C PUFAs into long-chain ones could be nega-
tive end-product regulation of the expression and/or
activity of some of the fatty acyl elongases or
desaturases, in particular at the first two steps of the
pathway of metabolic conversion of 18C PUFAs into
long-chain ones. If this is correct, a high dietary intake
of long-chain PUFAs from animal foods would be
expected to lead to a corresponding depression of the
capacity to convert 18C PUFAs from plant foods into
long-chain PUFAs. This mechanism has been observed
in rat liver, though not in the rat brain [40]. Yet end-
product inhibition of the expression or activity of these
enzymes can not explain the observations from Crete,
when the LA/ALA ratio of human blood plasma
cholesteryl esters is compared with that of olive oil,
since most people there do not subsist on vegan or lac-
tovegetarian diets, and the average intake of long-chain
PUFAs from animal foods is most likely fairly high.
Could geographical differences in micronutrient intake lead
to geographical differences in the extent of ALA conversion
into EPA and DHA, with this conversion being better in
warm countries than in Canada and northern Europe?
We have suggested as an alternative (but still entirely
hypothetical) explanation that there might be large geo-
graphical variations, due to differences in soil chemistry,
in the intake of some micronutrient (presumably some
essential trace element) that is needed for the metabolic
conversion of 18C PUFAs into long-chain ones, with the
average intake of the micronutrient concerned being
much lower in Canada than in Crete [41]. The trace ele-
ment vanadium (V) could be a possible candidate, since
it can occur in several oxidation numbers [42], and its
bioavailability for uptake into plant roots, similarly as
for chromium (Cr) [43], depends heavily on redox equi-
libria in the soil [44]. Vanadate (VO4
—)i ss o m e w h a t
more soluble and more bioavailable for the plants
(because of the chemical similarity between vanadate
and phosphate, as regards their binding to membrane
transporters), compared to vanadyl ions (VO
++). Vanadyl
ions are only slightly soluble [45], are tightly bound to
soil organic matter [46,47], and have most likely no root
uptake system of their own (for active transport into
plant roots).
Vanadium concentrations in plant foods, e.g. cereal
grains, are typically even lower than the Cr concentrations
in areas with much organic matter in the topsoil, such as
the wheat-growing areas of central North America [48],
this in spite of V having a larger average concentration
(60 ppm) than Cr (35 ppm) in the rocks of the upper con-
tinental crust [49]. More than half of 34 samples of wheat
grain from 12 different locations in North America were
found to contain less than 6.5 ppb (microgram/kg) V, and
the highest level was 20.0 ppb [48]. In the same study,
Cr concentrations ranged from 3 to 43 ppb with a mean
of 17 ppb [48]. But unrefined plant foods that have been
produced in warmer countries where the soil contains lit-
tle organic matter (because of faster microbial degradation
when the soil temperature is higher), such as unrefined
cane sugar, can have much higher concentrations both of
Cr and V, compared to North American wheat [48]. In a
study of Cr concentrations in molasses and unrefined,
brown, and highly refined sugar from several countries,
the mean values obtained were 266 +/- 58 ppb for the
molasses, 162 +/- 36 ppb for the unrefined sugar, 64 +/- 5
for the brown sugar, and 20 +/-3 ppb for the refined
(white) sugar [48]. Similarly, barley from Iraq has been
reported to contain about 100-200 times more Cr [50]
than barley from Finland [51]. Barbados brown sugar was
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white sugar [48]. Fish meal appears to be an exceptionally
good source of vanadium, with 2700 ppb having been
reported for herring fish meal [48]. This may reflect the
relatively high dissolved V concentration in seawater
(much higher than for Cr) [52], with vanadate probably
being taken up by algae by the same ATP-dependent
membrane transport system (or systems) that is used for
uptake of phosphate, arsenate and perhaps selenite.
Vanadium can thus be expected to be more bioavail-
a b l ef o ru p t a k eb yt h ep l a n t so nC r e t et h a ni nC a n a d a .
The climate on Crete is warmer and the soil therefore
contains less organic matter than in Canada; at the same
time the average soil pH is also most likely fairly high.
And V has general chemical properties that presumably
could make it suitable to function as a catalyst for some
of the kinetically more difficult redox reactions taking
place in living organisms, like fatty acyl desaturation.
If this vanadium hypothesis (for explaining poorer con-
version of ALA into DHA in Canada compared with
Crete) can be confirmed, an important implication would
be that pregnant and lactating women in Canada would
probably have a much higher requirement for long-chain
PUFAs from their diet compared to, say, women in
Nigeria or Tanzania. But it also means for the latter
women that if they as a consequence of poverty can not
obtain enough long-chain PUFAs from animal foods, it
may be even more important than for Canadian women
that their intake of ALA is adequate. Also the LA/ALA
ratio in their total diet should not be too high, to ensure
enough endogenous synthesis of DHA, compared with
the growth requirement of their foetus or baby (for
ensuring normal development of the brain of the latter).
I tc o u l dp o s s i b l ya l s om e a nt h a tt h e r em i g h tb ean e e d
for internationally accepted regulatory guidelines, making
it mandatory for all companies selling vegetable fats and
oils directly to consumers on markets in low-income
countries to ensure that the omega-3 fatty acid (ALA or
sum EPA + DPA + DHA) concentrations of their pro-
ducts should not be below some lower threshold value
and that the LA/omega-3 fatty acid ratio similarly should
not exceed some upper threshold value, with both
threshold values being determined by the regulatory
agency (or agencies) concerned. Taking unrefined palm
oil as an example, this could in principle very easily be
achieved by mixing the palm oil with a modest quantity
of linseed oil and/or good quality fish oil.
Effects of membrane lipid fatty acid composition on
membrane fluidity and on the rates of electron transport
through chloroplast and mitochondrial membranes
In their natural habitats, herbivorous or omnivorous ani-
mals acquire much of their intake of ALA from green
leaves, which normally have a surplus of ALA over LA in
their membrane lipids [53]. This is a great paradox, given
the enormous oxidative stress normally associated with
photosynthesis (i.a. as a consequence of the very high O2
partial pressure, higher than in ambient air, and of the
very abundant formation of singlet oxygen [53]). But it
can probably be explained as a result of the effect of dif-
ferent fatty acids on the fluidity properties of the thyla-
koid (inner chloroplast) membrane lipids. These have a
high concentration of ALA, making the membrane more
fluid, especially at low temperature, compared with what
would result from a similar concentration of LA, which is
important for the cold tolerance of the plants [54-56].
Higher membrane fluidity permits faster diffusion of
plastoquinone between different protein complexes in
the thylakoid membranes, which means faster electron
transport through the photosynthetic apparatus. Plasto-
quinone has a function in the chloroplasts similar to that
of ubiquinone in our mitochondria [53]. Fast electron
transport through the thylakoid membranes seems in this
particular context to be an even more important priority
for the plants, compared to antioxidant protection
(which they can achieve by several other methods).
The freezing point of vegetable fats and oils decreases -
for a given average number of C atoms per fatty acyl
group - as the average number of double bonds per fatty
acyl group is enhanced. Marine oils with high concentra-
tions of the long-chain omega-3 PUFAs EPA and DHA
(e.g. cod-liver oil) have especially low freezing tempera-
tures. The effect of different PUFAs on the fluidity prop-
erties of biological membranes is probably very similar to
what can be observed in more easily observable edible
fats and oils. The large average number of double bonds
per fatty acyl group that is typical of marine animals
(with much long-chain omega-3 PUFAs) can therefore be
interpreted, at least in part, as an adaptation to low ambi-
ent temperature, making it possible for fishes like capelin
(Mallotus villosus), salmon, herring and cod to swim fast
(with rapid electron transport through their mitochon-
drial respiratory chains), even when the seawater tem-
perature is low.
Why is there so much DHA in the human brain, testicles
and spermatozoa?
It is not unreasonable to suggest that the same mechan-
ism also can explain why there is so much DHA in the
membrane lipids in mammalian brains [57,58], as well
as in the testicles [59] and spermatozoa [60,61].
For the brain, there is probably a double advantage to be
gained, if the Ohmian resistance to lateral electron trans-
port through the inner mitochondrial membrane can be
minimized by improvement of the fluidity properties of
the membrane. One the one hand, this must be expected
to help to enhance the maximal mitochondrial ATP pro-
duction capacity per gram tissue when some part of the
brain is activated. This, in turn, may presumably help to
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when some special part of it is activated. On the other
hand, it must also be expected to help to decrease the rate
of mitochondrial production of reactive oxygen species
(ROS) for a given rate of ATP production. A reduction of
the rate of mitochondrial ROS production when the fluid-
ity of the inner mitochondrial membrane is improved is
most likely achieved by a double mechanism:
(a) by counteracting accumulation of electrons at the
top of the respiratory chain (in complex I) because they
can flow with less Ohmian resistance from complex I to
cytochrome c oxidase when the membrane is more fluid;
t h i sm e a n sr e d u c t i o no ft h er a t eo fs u p e r o x i d ea n i o n
radical generation by reaction between molecular O2 and
redox-labile groups (iron-sulphur and/or flavine) in com-
plex I (that happens when the latter are in a reduced
state),
(b) by helping the cell to maintain a given rate of ATP
production at a lower intramitochondrial O2 partial
pressure (because of faster electron supply to cyto-
chrome c oxidase). This will also help to reduce the rate
of superoxide anion radical production by reaction
between O2 molecules and complex I.
In the testicles, germ cells multiply at a very high rate
before they mature into fully differentiated spermatozoa.
Cell growth is highly ATP-dependent; at the same time
there must also be good reason to protect the DNA of
the germ cells as well as possible from damage caused
by ROS. Improving the fluidity of the mitochondrial
inner membranes of the germ cells might then presum-
ably be a good strategy for minimizing the ratio between
the rates of mitochondrial ROS production and mito-
chondrial ATP production.
After the spermatozoa have been discharged in the
female genital tract, there will be a fierce competition - in
a true evolutionary, Darwinian sense - to be the first one
to reach their target, which is a competition that only
one of them (among the huge number of sperms) can
win. In species where multiple matings involving more
than one partner are common, it must be expected that
males that produce spermatozoa that for genetic reasons
have larger ATP production capacity and therefore can
swim faster will have a marked Darwinian fitness advan-
tage compared to such males who produce spermatozoa
with mitochondria that have a lower ATP production
capacity. The same mechanism would, moreover, also be
expected to favour males who have better-functioning
sperm mitochondria because they are younger and there-
fore have less age-related mutations in their sperm mito-
chondrial DNA.
Enhancement of the rate of ROS-induced mutagenesis
in these organs is a serious matter, even more so when
it happens in the testicles than when it happens in the
brain. When the rate of mitochondrial mutagenesis is
enhanced in the brain, a likely consequence will be
higher risk and earlier onset of various age-related
degenerative brain diseases, such as Alzheimer’s disease
and Parkinson’s disease. However, when the same hap-
pens in the testicles, it can not be expected that nuclear
DNA will be spared when the rate of ROS production is
enhanced in the mitochondria owing to abnormal com-
position of the mitochondrial inner membrane lipids.
The consequence will then be enhancement of the rate
of ROS-induced germline DNA mutations. This will
directly affect the health of countless future generations,
especially when it occurs at a population level (because
of a change in the composition of the average diet eaten
by the whole population) and not affects just a few
unfortunate individuals (as in the case of occupational
exposure to ionizing radiation for astronauts or workers
in uranium mines). In a worst case scenario, it may
even be the survival of our species that could be at
stake if the total burden of germline mutagenesis
becomes too high in both men and women.
Possible role of mitochondrial membrane fluidity in
cardiac and skeletomuscular diseases, in neurodegenerative
diseases including peripheral neuropathies, and in diabetes
type 2
Most of the other cells in the human body lack the
unique capacity for DHA accumulation in their mem-
brane lipids that we find in the central nervous system,
the retina and the testicles. But it must be expected that
even in these more normal cell types (considering the
fatty acid composition of their mitochondrial membrane
lipids), there must be an effect of the dietary omega-6/
omega-3 fatty acid ratio, probably for both the 18C and
long-chain PUFAs, on the omega-6/omega-3 fatty acid
ratio and the fluidity properties of their inner mitochon-
drial membrane. This would also influence the Ohmian
resistance to electron transport from complex I to cyto-
chrome c oxidase. Enhancement of this resistance would
directly lead to increased “damming up” of electrons in
complex I, which must in turn be expected (other fac-
tors being equal) to lead to enhancement of the rate of
intramitochondrial ROS production.
The fluidity of mitochondrial membranes depends also
on other factors than their fatty acid composition, and
some of the changes associated with normal aging may
apparently lead to enhanced membrane rigidity, or
reduced fluidity [62]. In the heart, it has been found
that age-associated mitochondrial membrane changes
include increases in membrane rigidity, cholesterol,
phosphatidylcholine, omega-6 PUFA and 4-hydroxy-2-
nonenal, and decreases in omega-3 PUFA and cardioli-
pin [62]. It might be speculated that the age-associated
enhancement in the omega-6/omega-3 PUFA ratio, even
when the fatty acid composition of the diet is constant,
is something that happens as a result of preferential
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ROS production is enhanced as a direct consequence of
the aging process [63]. We have ourselves similarly
found in experiments with broilers that the omega-6/
omega-3 long-chain PUFA ratio of the meat depends
upon the selenium (Se) intake of the animal, with better
Se status being associated with enhancement of the
DHA concentration in the meat. This is most likely a
consequence of improved protection of DHA against
degradation by processes of lipid peroxidation [18]. A
similar protective effect of good Se status against DHA
degradation by peroxidation may in principle be
expected to occur also in aging humans, while enhance-
ment of the rate of mitochondrial ROS production
would be expected to have an effect in the opposite
direction in both species.
The above-mentioned effects of aging on the properties
of membrane lipids in the heart have been shown in ani-
mal studies to be exaggerated by a diet rich in AA [62].
They have profound consequences for the efficacy of
membrane proteins involved in ion homeostasis, signal
transduction, redox reactions and oxidative phosphoryla-
tion [62]. However, some of the age-related detrimental
changes may be beneficially modified by dietary interven-
tion [62]. Diets rich in omega-3 PUFA have been reported
to reverse the age-associated membrane omega-6/omega-3
PUFA imbalance and also the age-associated dysfunctional
Ca
++ metabolism, at the same time as they improve the
efficiency of mitochondrial energy production and also the
tolerance of ischemia and reperfusion [62,64].
Another group has also observed in animal experi-
ments that a lower omega-6/omega-3 fatty acid ratio in
the myocard was associated with faster recovery of
mitochondrial energy metabolism and myocardial pump
function during reperfusion following experimental
ischemia [65]. The tolerance of the myocard to ischemia
followed by reperfusion is thus improved by a reduction
in the dietary omega-6/omega-3 PUFA ratio, at least as
far as the long-chain PUFAs are concerned (i.e. the AA/
(EPA + DPA + DHA) ratio) [65,66]. But one may in
principle expect that a reduction of the LA/ALA ratio of
the diet also could have an effect going in the same
direction - with ALA having a similar effect also in our
mitochondria, when it replaces LA, as it has in the thy-
lakoid membranes of the plants.
Similar effects may in principle be expected also in
other organs, where enhanced mitochondrial ROS pro-
duction as a consequence of abnormally rapid (or patho-
logical) mitochondrial DNA aging could represent an
important part of the pathogenetic mechanism of per-
haps several different degenerative diseases, most likely
including type 2 diabetes [67]. It is not implausible that
this also could play a role in the etiopathogenesis of ske-
letomuscular diseases often affecting elderly people,
including pains associated with skeletal muscle spasms
or overload, and perhaps also the degenerative changes
affecting cartilage in patients suffering from osteoarthri-
tis. In both cases, it is not unreasonable that changes in
inner mitochondrial membrane lipid composition could
interact synergistically with mitochondrial DNA muta-
tions (and sometimes also cytokines) as causes of
enhanced mitochondrial ROS production.
Furthermore, enhancement of mitochondrial ROS pro-
duction must be expected to interact synergistically with
factors such as Se, glutathione, taurine, carnosine or
other antioxidant nutrient depletions that lead to
impairment of the antioxidant defense capacity of the
muscle or cartilage cells. This would apply also for cells
in the brain (which might be important in neurodegen-
erative diseases such as Alzheimer’s disease) and in per-
ipheral nerve fibres (which might be important in
diabetic peripheral neuropathy and other cases of
C-fibre dysfunction), as well as for the beta-cells in the
pancreas, which means it might well also be important
in the etiopathogenesis of type 2 diabetes. There is good
reason to hope that multifactorial therapeutic interven-
tions for reducing the pathologically elevated mitochon-
drial ROS production while optimizing the cellular
capacity for scavenging ROS might be helpful in all of
the above-mentioned diseases, at least for secondary
prophylaxis by reducing their rate of further progres-
sion, but in some cases (e.g. in common pain conditions
associated with C-fibre dysfunction, and perhaps type 2
diabetes) also by partial symptom reversal.
While oleic acid replacement of LA would be expected
to have the opposite effect on membrane fluidity to that
happening when ALA or some long-chain PUFA
replaces LA in the same membrane lipid position, it
might be speculated that such detrimental effects of
oleic acid on membrane fluidity could be partly or
entirely compensated for by oleic acid substitution not
only for PUFAs, but also for saturated fatty acids in the
membrane lipids. Oleic acid substitution for a saturated
fatty acid, like stearic acid (with the same number of C
atoms), in a position not normally occupied by PUFAs
would presumably lead to reduction of the membrane
fluidity. The same can also be expected to happen when
a saturated fatty acid with shorter chain length replaces
one with longer chain length, as in the case of palmitic
acid replacing stearic acid. It seems, however, that there
is little research literature dealing with these questions.
It is an important topic probably deserving far more
intensive research attention than it has received so far.
Dietary AA/(EPA + DPA + DHA) and ALA/LA ratios, gene
expression and eicosanoid biosynthesis
While 18C fatty acids are found in both animal and
plant foods, with a large proportion of the total dietary
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PUFAs come nearly exclusively from animal foods
(especially meat, fish and eggs) and dietary supplements
made from seafish, such as cod-liver oil and fish oil cap-
sules. The ratio between dietary intakes of long chain
omega-6- and long chain omega-3 fatty acids is therefore
in large measure determined by the long chain omega-6/
omega-3 fatty acid concentration ratio of the different
animal products that we commonly eat, as well as by
the frequency of eating animal foods with either high or
low long-chain omega-6/omega-3 fatty acid ratios.
For people living on such mixed diets that are com-
mon in the industrial countries, endogenous synthesis of
long-chain PUFAs from 18C PUFAs is also important,
and the ratio between the concentrations of long chain
omega-6- and long chain omega-3 fatty acids found in
our tissue lipids will be similarly dependent on both the
magnitude of dietary intakes of long-chain PUFAs as
such and the magnitude of dietary intakes of LA and
ALA. For people especially in poor countries who for
economic reasons can not afford to eat much animal
food, it must be expected that endogenous synthesis of
l o n g - c h a i nP U F A sf r o mL Aa n dA L Aw i l ln o r m a l l y
dominate over dietary intakes of long-chain PUFAs as
such. It must therefore be very important for the general
health situation in these countries that the edible fats
and oils eaten by less affluent people should have an
optimal fatty acid composition in which the omega-6/
omega-3 ratio is not too high. As earlier explained, this
applies also to the normal development of the brain of
foetuses and children.
The ratio between long-chain omega-6 and long-chain
omega-3 fatty acids is now considered to be so high in
many of the western societies that it substantially
increases the mortality and/or morbidity associated with
several non-communicable diseases. This includes some
of the leading causes of death in the countries con-
cerned, such as coronary heart disease and malignant
arrhythmia [68,69]. This happens not only because of
enhanced incidence for some of the diseases concerned,
e.g. for acute thrombotic events, but also because of
symptom aggravation or more rapid progression of
already established disease (e.g. intensification of skeleto-
muscular pains or more rapid progression of colon can-
cer as a consequence of prostaglandin overproduction).
One of the explanations for the harmful effect of over-
abundance of omega-6 fatty acids in the diet has already
been mentioned, viz. the effect of changes in the AA/
(EPA + DHA) ratio in the lipids of the inner mitochon-
drial membrane on the fluidity properties of the mem-
brane. A high AA/(EPA + DHA) ratio leads to stiffening
of the membrane and enhanced Ohmian resistance to
the transport of electrons from complex I to cytochrome
c oxidase. This will in turn lead to enhancement of the
rate of mitochondrial ROS production. Another impor-
tant reason is the different effects that omega-6 fatty
acids and omega-3 fatty acids have on gene expression.
Omega-3 fatty acids hinder the expression of inflamma-
tory genes [70], whereas omega-6 fatty acids have proin-
flammatory effects [70].
Inflammation can take place within the vascular walls
and plays a role in modulating the effect of insulin and
control of inflammatory gene expression and lipid meta-
bolism [70]; this is important not only in connection with
diabetes type 2, but also as a part of the disease mechan-
ism during progression of atheromatosis/atherosclerosis
[70]. Omega-3 fatty acids decrease the endothelial
responsiveness to proinflammatory and proatherogenic
stimuli by modulating the expression of adhesion mole-
cules and cytokines important for the processes collec-
tively denoted as “endothelial activation” [71]. Studies on
postprandial inflammation (which is now considered an
independent risk factor for diseases such as atherosclero-
sis and insulin resistance) indicate that each meal triggers
an inflammatory response, and that the ratio between
omega-6 and omega-3 fatty acids is an important deter-
minant of the magnitude of this postprandial inflamma-
tory response [72].
It should also be noted that another fatty acid, viz. oleic
acid, has been reported to have protective effects similar
to those which the long-chain omega-3 fatty acids have
been demonstrated to have on endothelial cells, namely by
reducing rates of intracellular generation of reactive oxy-
gen species (ROS) [73] and counteracting the activation of
nuclear factor-kappaB [74]. This may probably help to
explain the strongly protective effect against myocardial
infarction that was found for a modified Mediterranean
diet in the Lyon trial, compared to such “prudent diets”
that were then commonly recommended to patients suf-
fering from coronary heart disease [75]. In this case, olive
oil had been partly replaced by a margarine rich in rape-
seed oil, which was rich in oleic acid as well as ALA.
Effect of the dietary AA/(EPA + DPA + DHA) and LA/ALA
ratios on the balance between thromboxane and
prostacyclin biosynthesis and on the total rate and effects
of prostaglandin biosynthesis in diseases other than
cardiovascular disease
Another important reason why overconsumption of AA
is harmful (especially when combined with low dietary
intakes of EPA and DHA) is the tendency for prosta-
glandin and thromboxane A2 overproduction in disease
situations, when the absolute intakes of arachidonic acid
(AA) and/or LA, the dietary ratio of AA to the sum of
EPA and DHA, or the ratio of LA to ALA in the diet
are too high. In a recent study of the specificities of
enzymes and prostanoid receptors toward EPA-derived,
3-series versus AA-derived, 2-series prostanoid sub-
strates and products, the largest difference was seen
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[76]. Under optimal conditions, it was found that puri-
fied COX-1 oxygenates EPA at a rate which is only 10%
of the rate for AA, while EPA significantly inhibits AA
oxygenation by COX-1 [76]. 2-fold to 3-fold higher
activities or potencies with 2-series versus 3-series com-
pounds were observed with COX-2, PGD synthase,
microsomal PGE synthase-1, and EP1, EP2, EP3 and FP
prostanoid receptors [76]. Surprisingly, it was observed
that AA oxygenation by COX-2 is only modestly inhib-
ited by EPA; COX-2 exhibits a marked preference for
AA when EPA and AA are tested together [76]. Also
unexpectedly (and contrary to the earlier belief that
thromboxane A3 (TxA3) is inactive), it was found that
TxA3 is about equipotent to TxA2 at the TPalpha
receptor [76]. These observations predict that increasing
the EPA/AA ratios in the phospholipids of human cells
would dampen prostanoid signalling, the largest effects
being on COX-1 pathways involving PGD, PGE, and
PGF. Production of 2-series prostanoids from AA by
COX-2 would be expected to decrease in proportion to
t h ec o m p e n s a t o r yd e c r e a s ei nt h eA Ac o n t e n to fp h o s -
pholipids that would result from increased incorporation
of omega-3 fatty acids such as EPA and DHA [76].
I ts h o u l db en o t e dt h a te v e ni nt h eC O X - 2p a t h w a y ,
one must expect much less stimulation of the EP1, EP2
and EP3 receptors if one starts with EPA rather than
AA. This is due to a multiplicative effect of less rapid
conversion of EPA into PGH3, less rapid conversion of
PGH3 into PGE3 and less potency of PGE3 at the recep-
tors (EP1, EP2 and EP3), compared with AA, PGH2 and
PGE2. However, as far as COX-2 is concerned, it is
important to recognize that AA competes not only with
EPA and DHA, but also with LA, ALA and oleic acid
for incorporation in the same positions in membrane
lipids. Enhancement of the EPA and DHA concentra-
tions at these positions will therefore not be attended by
a proportional reduction of the AA concentration. Thus
the best strategy for avoiding prostanoid overproduction
in disease situations where COX-2 is important must be
to reduce the intake of AA, rather than just enhancing
the intakes of EPA and DHA.
It should, furthermore, be taken into consideration
that not only do AA, EPA and DHA compete with each
other for binding to COX-1 and COX-2 (with EPA and
DHA inhibiting the conversion of AA into PGH2 and
AA and DHA inhibiting the conversion of EPA into
PGH3). but also 18C unsaturated fatty acids (especially
the 18C PUFAs, but also oleic acid) can bind to COX-1
and COX-2, albeit considerably weaker than the 20C
and 22C PUFAs, and can thus function as competitive
inhibitors of the conversion of 20C PUFAs into prosta-
glandins and thromboxanes [77-80]. Even though the
18C unsaturated fatty acids are fairly weak inhibitors of
20 C PUFA oxidation by cyclooxygenases, it should not
b ef o r g o t t e nt h a tt h e ya r ea r em u c hm o r ea b u n d a n t
than the latter, especially LA and oleic acid. A high total
intake of 18C PUFAs and oleic acid may thus help to
antagonize some of the harmful effects of over-intake of
AA from animal foods with unbalanced omega-6/omega-
3 fatty acid ratios. This is not just because of their
competitive displacement of long-chain PUFAs from
corresponding positions in the membrane lipids, but
also because of their effects as COX inhibitors. This
may be considered one of the (perhaps few) beneficial
effects of diets rich in LA in some, but not all disease
conditions. One should, on the other hand, not forget
the important role played by dietary LA as a precursor
used for endogenous synthesis of AA.
The long-chain PUFAs of animal foods appear to be
associated mainly with membrane lipids (plus blood
plasma lipoproteins), while the concentration of long-
chain PUFAs in the triglycerides of adipose tissue such
as lard is surprisingly low [16]. The somewhat paradoxi-
cal conclusion may be reached that it would probably be
better for many patients, when overproduction of pros-
taglandins is a major problem (e.g. in various pain con-
ditions), and when the omega-6/omega-3 ratio of some
animal food (e.g. pork meat) is too high, to eat meat
products containing much adipose tissue rather than
lean meat. It is thus possible that efforts to breed ani-
mals (e.g. swine) with proportionately less adipose tissue
compared with muscle (because this was thought to be
better for the health of the consumer) may have been
largely futile, as far as the intended health effects are
concerned. It would probably be much better, if we
want to minimize prostaglandin production (e.g. in a
patient with chronic pain, or a patient with metastatic
colon cancer), to recommend animal foods that have a
low omega-6/omega- 3f a t t ya c i dr a t i oa tt h es a m et i m e
as the proportion of adipose tissue to muscle is high.
T h i sc o u l db ed o n ee s p e c i a l l yw h e nt h ea d i p o s et i s s u e
from the animal has a low concentration of LA with
higher relative concentrations of oleic acid, ALA and
saturated fatty acids (e.g. meat from sheep or goats that
have been slaughtered during the autumn after they
have been fattened on mountain pastures during the
whole summer), while animal adipose tissue containing
too much LA relative to the sum of ALA, oleic and stea-
ric acid (since stearic acid can partly be converted into
oleic acid following intestinal absorption in the human
body) should not be similarly recommended.
LA has been reported to function as a much stronger
inhibitor of COX-2 than COX-1 [78,79], while for ALA
t h e r ei sm u c hl e s sd i f f e r e n c eb e t w e e ni t sC O X - 2a n d
COX-1 inhibitory activities [78]. Since endothelial COX-
2 is important for prostacyclin (PGI) synthesis [81],
while platelets contain only COX-1, one must expect
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ratio will depress the synthesis of prostacyclin in the
endothelium much more than it depresses the synthesis
of thromboxanes in the platelets. This must in turn be
expected to enhance the risk of adverse thrombotic
events, e.g. in the brain, given the strong prothrombotic
effect of thromboxanes [82] and the strong antithrom-
botic effect of the prostacyclins [82]. Here, the effect of
a high total dietary intake of LA is similar to that of a
high dietary AA/(EPA + DHA) ratio, and also similar to
the effect of some selective COX-2 inhibitors, such as
celecoxib and valdecoxib, that have now been retracted
from the market because of their cardiovascular side
effects [83].
Should enhanced intake of oleic acid be recommended as
a strategy for antagonizing the effects of too much
arachidonic acid in western diets?
In theory, it should be possible to use enhanced dietary
intakes of 18C polyunsaturated fatty acids (LA and
ALA) or oleic acid to displace AA, rather than reducing
the AA intake, for reducing its concentration in the
membrane lipids of human cells. At the same time the
18C unsaturated fatty acids will also function as compe-
titive inhibitors of the cyclooxygenases. It is conceivable
that a high intake of LA for this reason could be protec-
tive against cardiovascular disease in populations who
consume too much AA and too little EPA and DHA,
even though the role of LA as a precursor for endogen-
ous synthesis of AA would rather appear to suggest the
opposite. This applies also to the stronger inhibitory
effect of LA on COX-2 compared with COX-1, as
explained above, which is another possible reason why a
high intake of LA might enhance the risk of adverse
thrombotic events rather than decrease it. Another
important disadvantage of enhancing the total intake of
other polyunsaturated fatty acids (even LA with only
two double bonds in its side chain) for reducing the AA
concentration of human membrane lipids, rather than
reducing the dietary intake of AA, is that this method
must be expected to lead to enhanced lipid peroxida-
tion, other factors being equal.
This objection, however, does not apply to enhancing
the dietary intake of oleic acid as a possible strategy for
reducing the AA concentration of the membrane lipids in
leukocytes, platelets, endothelium and other human cells.
This is because oleic acid with only one double bond is
not easily peroxidised, like all polyunsaturated fatty acids
(with the vulnerability to oxidative attack increasing with
the number of double bonds per molecule). Instead it is
very resistant to non-enzymatic oxidative attack. Enhance-
ment of the oleic acid/polyunsaturated fatty acid concen-
tration ratio (e.g. the oleic acid/LA ratio) at a given
position in phosphatidylcholine or other lipid molecules
will therefore make the lipid molecule concerned less vul-
nerable to non-enzymatic oxidation. This applies both to
lipid molecules in membrane structures inside the cells
(e.g. in the mitochondria) and to those in plasma lipopro-
teins. There is also good reason to expect that it may
apply not only to the susceptibility of lipid molecules to
peroxidation by free radical reactions, but also to their sus-
ceptibility to oxidation by peroxynitrite, which is a potent
and highly reactive oxidant, but not itself a free radical
(although it may give rise to free radicals by secondary
reactions).
Proatherogenic and mutagenic effects of products of
lipid peroxidation
In the blood and the vascular walls, it appears now to be
well documented that oxidized LDL is much more
atherogenic than non-modified LDL [84,85]. But it must
also be expected that enhanced lipid peroxidation every-
where (both in the blood, in the vascular walls and in any
other cell type) will lead to enhanced production of alde-
hydes that are mutagenic, such as malondialdehyde [86],
crotonaldehyde [87], acrolein [88], and 4-hydroxynonenal
[89]. This must in turn be expected to lead to enhance-
ment of the rate of accumulation of deleterious muta-
tions in both nuclear and mitochondrial DNA. Increase
in the rate of mutations in the nucleus enhances the risk
of cancer; increase of the rate of mutations in mitochon-
drial DNA means abnormal enhancement of the rate of
mitochondrial DNA aging [63,90].
It is possible, however, that the mutagenic effects of
some of the aldehydes concerned could be much larger
in the mitochondria than in the nucleus because of less
efficient DNA repair in the mitochondria, which have a
more restricted repertoire of DNA repair mechanisms
compared to the nucleus. These mutations therefore
could be more important as causes of accelerated aging
rather than as causes of cancer. 4-Hydroxynonenal has,
moreover, also been reported to function as a potent
inducer of the immunosuppressive [91] and fibrogenic
[92] cytokine TGF-beta, which might be highly relevant
in the pathogenesis of arteriosclerosis.
Role of selenoprotein P as a protectant against plasma
lipoprotein peroxidation, atheromatosis and thrombosis
As far as the blood lipids are concerned, the rate of LDL
oxidation presumably depends on several other factors
in addition to its fatty acid composition (i.e. its PUFA/
oleic acid ratio, with LA being most important among
the PUFAs for people living on a normal European or
North American diet). The rate of production of peroxy-
nitrite when superoxide anion radical from endothelial
NAD(P)H oxidase reacts with NO (also produced by
endothelial cells, which is something we shall return to
and discuss in more detail later) is probably one of the
most important factors governing the rate of LDL oxida-
tion, if not the most important one. Anything that can
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oxidase must also be expected to enhance the rate of
LDL oxidation, while anything that can be done in
order to correct pathologically elevated endothelial ROS
and peroxynitrite production will be helpful for protec-
tion against atheromatosis, arteriosclerosis and
thrombosis.
Another factor that is most likely very important for
the rate of LDL oxidation, is the activity of the antioxi-
dant protective enzyme selenoprotein P [93,94]. This
protein has a function in extracellular environments
similar to that which GPx-4 (also called phospholipid
hydroperoxide glutathione peroxidase) has inside the
cells, reducing organic hydroperoxides associated with
membrane molecules or with plasma lipoproteins
[93,94]. But GPx-4 and selenoprotein P use different
reductants, since GPx-4 uses GSH, while selenoprotein
P prefers reduced thioredoxin [95].
It should be noted that human extracellular fluids also
contain thioredoxin reductase [96,97], needed for regen-
eration of reduced thioredoxin after its oxidation in the
selenoprotein P reaction. Thioredoxin reductase is both a
flavoprotein and a selenoprotein [98,99]. It contains a
selenocysteyl group and a cysteyl group in adjacent posi-
tions [99], making it possible for these groups to form
chelate complexes with heavy metal atoms. Thioredoxin
reductase is therefore extremely vulnerable to inhibition
by toxic metals. It is more sensitive by a factor of 1000 or
more than GPx-1 and glutathione reductase to inhibition
by aurothioglucose or another organic gold complex
called auranofin [99]. While GPx-1 is a selenoprotein
containing isolated selenol groups (without opportunities
for chelate formation), glutathione reductase is an ordin-
ary dithiol protein, with which chelates can be formed by
simultaneous coordination of a heavy metal atom with
2 sulphur atoms.
The human selenoprotein P gene codes for 10 seleno-
cysteyl groups per molecule [100]. But it is often not fully
saturated with Se, since inadequate Se intake can lead to
premature termination of translation for some of the
molecules [101-103]. It is apparently not known if there is
only one active site for hydroperoxide reduction per mole-
cule, one for every Se atom (unless the site concerned is
blocked by a heavy metal atom), or an intermediate num-
ber of active sites (more than 1, but less than 10).
Selenoprotein P is a glycoprotein [102] that contains
also many basic aminoacyl groups (lysyl and histidyl
groups) [104] and many cysteyl groups [105]. It is
bound to the surface of endothelial cells [106,107] and
to LDL [108], most likely as a result of electrostatic
attraction between positively charged aminoacyl groups
on the selenoprotein P molecule and negatively charged
groups, e.g. phosphate groups in phospholipids, both in
LDL and on the surface of the endothelial cells, as well
as in heparin [104,109]. The binding of selenoprotein P
to LDL can presumably explain why the blood becomes
Se-depleted when LDL is removed from the plasma of
hypercholesterolemic patients by LDL apheresis
[110,111]. Selenocysteyl and cysteyl groups are found in
such relative positions that the selenol and thiol groups
can be oxidized and form at least two selenenylsulfide
linkages per molecule [112]. It would be expected that
the selenocysteyl and cysteyl groups concerned also may
bind toxic heavy metals avidly, forming very stable che-
late complexes with the heavy metal atoms. This is con-
firmed by observations, showing strong binding of toxic
heavy metals, such as silver, mercury and cadmium, to
selenoprotein P [113]. Selenoprotein P was found to
bind the metals concerned, even when they had already
formed complexes with selenide ions before binding to
the protein [113].
The concentration of selenoprotein P in human blood
plasma depends on the Se intake [114,115], with a Se
intake of at least 100 microg/day being needed for
saturation in adult persons [116]. The Se intake in most
parts of Europe is less than that needed for saturation of
blood plasma with selenoprotein P [117]. But the con-
centration of selenoprotein P in blood plasma can also
be changed because of disease, such as prostate cancer
[118] or sepsis [119].
It must be theoretically expected that there will be a
synergistic (multiplicative) interaction between low Se
intake (leading to undersaturation of the blood plasma
with selenoprotein P), large exposure to toxic heavy
metals (which may be expected to lead to simultaneous
inhibition of selenoprotein P and extracellular thiore-
doxin reductase), a high dietary LA/oleic acid intake ratio
and high rates of superoxide anion radical production
from endothelial NADPH oxidase as causes of more
rapid LDL oxidation - with a high rate of LDL oxidation
leading in turn to high rates of atheromatosis develop-
ment. Against this background it is not unreasonable to
speculate that excessive exposure to a number of toxic
metals from a wide range of different sources may have
been one of the main causes of the post-war epidemic of
coronary heart disease both in North America and Wes-
tern Europe. These include lead from car exhaust and
from drinking water (especially in the British Isles), as
well as mercury and silver from dental amalgam fillings
and cadmium from acid rain, commercial fertilizers and
tobacco smoke.
All the above-mentioned toxic metals would be
expected to bind strongly to the chelate-forming selenol
and thiol groups in both thioredoxin reductase and sele-
noprotein P (and also, albeit not equally strongly, to
chelate-forming thiol groups in thioredoxin). It is possi-
ble that their relative importance as causes of enhanced
LDL oxidation and atheromatosis, both at the individual
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strongly on differences in their relative binding strength
to these enzymes than on differences in their abun-
dance. If this hypothesis is correct, it means that lead,
which is the most abundant of these toxic metals when
considering both its average abundance in the Earth’s
continental crust [49] and as an environmental pollu-
tant, could have been more important than any other
toxic metal as a contributory cause of LDL oxidation,
atheromatosis and coronary heart disease. This hypoth-
esis would appear to be in reasonably good agreement
with what is known about the historical curves both for
coronary heart disease mortality and for the use of lead
as an additive in gasoline in Western Europe, compared
to North America. The use of lead as an additive in
gasoline started earlier and ended earlier in the United
States than it did in the countries of Western Europe.
And the epidemic of coronary heart disease has followed
a similar time course with both its start and its culmina-
tion occurring earlier in the United States than in
Western Europe.
Redox regulation of prostaglandin biosynthesis
The rate of prostaglandin (PG) biosynthesis is regulated
at two consecutive enzyme reaction steps, first at the
level of liberation of eicosanoid precursor fatty acids by
hydrolysis of membrane lipids (which is often catalyzed
by phospholipase A2) ,a n dn e x ta tt h el e v e lo ft h e
cyclooxygenase (COX, or prostaglandin H synthase)
reaction, where precursor fatty acids (such as AA or
EPA) are converted into the corresponding PG endoper-
oxide. For example, prostaglandin H1 (PGH1)i sf o r m e d
from dihomo-gamma-linolenic acid, while PGH2 is
formed from AA and PGH3 from EPA. PGHs are them-
selves unstable, but are rapidly converted by other
enzymes to form other prostaglandins (such as PGE,
PGD, PGFalpha or PGI) or thromboxanes.
There are different isozymes of phospholipase A2 with
different localization (intracellular or extracellular) and
regulation, some being activated by Ca
++, while others
are Ca
++-independent. Some of these enzymes are acti-
vated, or their expression is enhanced, by oxidative
stress [120,121], which for a number of different reasons
will commonly accompany inflammatory reactions
[90,122]. This is one of the reasons why the synthesis of
prostaglandins or other eicosanoids (such as leuko-
trienes) is enhanced in all inflammatory diseases, includ-
ing allergic diseases and asthma (where leukotrienes are
very important).
The cyclooxygenases (COX-1 and COX-2) must be
oxidized for activation, and H2O2, organic hydroperox-
ides and peroxynitrite can all function as activators
[77,90,123-125]. These activators are scavenged by the
group of selenoproteins called glutathione peroxidases
(GPx) [126,127], which are potent inhibitors of cycloox-
ygenase activation [77]. But activation of COX mole-
cules will simultaneously start a slower process of
suicidal inactivation of the same enzyme molecules [77],
which means that each COX molecule can on average
only make a limited number of PGH molecules. When
GPx counteracts activation of this enzyme, it will simul-
taneously also inhibit its suicidal inactivation, similarly
as has been observed with various biological and syn-
thetic antioxidants [77] that not only inhibit COX acti-
vation (because they may reduce the formation of
hydroperoxide activator molecules or scavenge peroxyni-
trite), but also inhibit the irreversible suicidal inactiva-
tion of COX.
The main reason why it is still possible for prostaglan-
din production to be much enhanced during inflamma-
tory reactions, in spite of the limited number of PGH
molecules that can be made per COX molecule before
the latter is inactivated, is the possibility of upregulating
expression of COX-2 (i.e. enhancing the production of
new enzyme molecules) under such conditions when the
rate of its suicidal inactivation is enhanced. The expres-
sion of COX-2 in leukocytes is under multiple regulation
by several different transcription factors, including the
oxidatively regulated [128] transcription factor nuclear
factor-kappaB( N F - kappaB) [129,130], and also other
oxidatively regulated transcription factors. So when oxi-
dative stress enhances the rate of irreversible suicidal
inactivation of COX-2, it will simultaneously enhance the
rate of production of new enzyme molecules.
Low Se intake is associated with reduced activity of GPx
in many cell types and organs [126]. This may in turn lead
to eicosanoid overproduction because of the combination
of more phospholipase A2 expression or activation, more
rapid COX activation and enhanced expression of COX-2.
The same must also be expected to happen when cells are
undersaturated with reduced glutathione (GSH), that func-
tions as the reducing substrate for GPx [126]. But since
GPx displays tert-uni ping pong kinetics [126], and 2 GSH
molecules are consumed for each molecule of oxidizing
substrate (e.g. H2O2) consumed in the same reaction, the
rate of oxidizing substrate removal (at a given concentra-
tion of the latter) depends on the second power of the
GSH concentration, while it depends only on the first
power of the concentration of the enzyme. It must there-
fore be expected that overconsumption of AA, low intake
of Se and GSH depletion will interact synergistically with
each other as causes of prostaglandin overproduction,
especially during inflammatory conditions where COX-2
expression is enhanced.
It may also be theoretically expected that GSH deple-
tion can be even more important than poor Se status as
a cause of prostaglandin or thromboxane overproduc-
tion. The latter can potentially lead to thrombotic
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easily develop in disease situations, especially because of
the combination of reduced food intake and enhanced
protein catabolism. It can not be expected that this
situation will be improved by giving the patients large
doses of drugs, such as acetaminophen (paracetamol),
that are partly metabolized by forming conjugates with
glutathione or other sulphur amino acid derivatives [82].
Can interactions between nutritional factors and alcohol
and a biphasic effect of alcohol itself on the blood plasma
GSH concentration help to explain why moderate alcohol
consumption protects against cardiovascular mortality in
some countries while excessive alcohol consumption
enhances it in Russia?
Alcohol abuse, especially when combined with a poor
diet and/or disease leading to enhanced protein and sul-
phur amino acid catabolism [131-135], can not be
expected to make the situation any better for patients
suffering from prostaglandin overproduction because of
GSH or other antioxidant nutrient depletion (which
might be very common, especially in such cases where
there is a synergistic interaction between alcohol abuse
and poverty as causes of poor health). Alcohol abuse
can deplete the liver of glutathione by a combination of
different mechanisms [136,137]. These include acute
inhibition of glutathione synthesis [136-138] and
enhanced GSH efflux to the blood [136-138], but most
likely also enhanced excretion of GSSG through the bile,
s i m i l a r l ya sh a p p e n sa f t e re x p o s u r eo ft h el i v e rt oo t h e r
oxidant stressors [139,140], when the alcohol-induced
oxidative stress in the liver [141,142] becomes too high
because of enhanced ROS production from several dif-
ferent sources [143-146].
It is possible, however, that moderate consumption of
alcohol, especially when taken in combination with pro-
tein-rich meals and when the antioxidant nutrient status
is good, may have a positive effect on blood GSH concen-
trations and hence on the GSH status in cells in other
parts of the body, outside the liver. This could happen
not only because of the stimulating effect of alcohol on
GSH efflux from liver cells to the blood, as explained
above, but also because alcohol enhances the expression
of the catalytic subunit of one of the enzymes participat-
ing in GSH synthesis in the liver, viz. gamma-glytamyl-
cysteine synthetase (which is also called glutamate-
cysteine ligase) [147]. This effect might perhaps outweigh
the more acute inhibitory effect of alcohol on GSH
synthesis and its effect on the rate of GSSG excretion to
the bile as long as the alcohol consumption is not too
high. It is not implausible that the stimulating effect of
moderate doses of alcohol both on the expression of the
catalytic subunit of gamma-glytamylcysteine synthetase
and on the efflux of GSH from liver cells to the blood
(which in combination would be expected to lead to
elevation of the blood plasma GSH concentration, espe-
cially when the alcohol is consumed in connection with
protein-rich hot meals) might in large measure explain
the protective effect of moderate alcohol-consumption
against coronary heart disease, metabolic syndrome and
diabetes mellitus that appears now to be well documen-
ted through epidemiological studies [148-150].
Prostaglandin biosynthesis, other lipid metabolites, pain
and drugs
Several prostaglandins and other eicosanoids function as
important sensitizers of C-fibres [90]. These are very
thin (unmyelinated) peripheral nerve fibres comprising
different subtypes with a number of different functions
both in normal physiological regulation and during dis-
ease processes. Some of them are important mediators
of nociceptive pain [151], but C-fibres can also secrete
neuropeptides (such as tachykinins and CGRP) that are
important mediators of inflammation [152-154].
Role of oxidized LA metabolites as agonists of the heat-
and acid-sensitive vanilloid pain receptor
It has recently been reported that four oxidized metabo-
lites of LA, viz. 9- and 13-hydroxyoctadecadienoic acid
(9- and 13-HODE), as well as 9- and 13-oxoODE, function
as agonist ligands of the C-fibre vanilloid receptor (also
called the capsaicin receptor) [155,156]. 9- and 13-HODE
can be produced from LA by the action of various (12S)-
lipoxygenase isozymes [157,158], followed by reduction of
the hydroperoxides first formed by enzymes such as GPx-4
or GPx-1, depending on whether the LA hydroperoxides
first formed are still bound to the membrane or not. 13-
HODE can, moreover, also be formed by 15-lipoxygenase
acting on LA [159], followed by GPx-catalysed reduction of
the hydroperoxide formed in the 15-lipoxygenase reaction.
The vanilloid receptor is activated by low extracellular
pH [160] and by noxiously high temperature (>43°C)
[161]. It is also activated by capsaicin, which is the active
substance in red pepper (Capsicum sp.) [162]. This pre-
sumably explains why foods rich in red pepper produce a
burning sensation in the mouth and throat (‘hot’ foods).
It has now been found that the activating effect of high
temperature on the vanilloid receptor is caused by activa-
tion of enzymes converting phospholipid-bound LA into
9- and 13-HODE [156]. This presumably means that
temperatures above 43°C must be associated with
12-lipoxygenase and/or 15-lipoxygenase activation (per-
haps in large measure as a consequence of incipient cell
death associated with lipoxygenase activation in the
mitochondria).
It should be expected that the quantities of 9- and
13-HODE that will be formed at a certain temperature
must depend on the concentration of LA in the mem-
brane lipids, with a higher LA/oleic acid ratio in the
membrane leading to enhancement of the quantities of
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lipoxygenase and 15-lipoxygenase have similar catalytic
mechanisms as for the first step of the cyclooxygenase
reaction, and they must therefore be activated by oxi-
dation in a similar way as is needed also for COX. It
has been reported that glutathione peroxidases (such
as GPx-1 and GPx-4) counteract the activation of
15-lipoxygenase and 12-lipoxygenase [163-165], simi-
larly as they counteract the activation of COX
[77,163,164] and 5-lipoxygenase [166-168], with the
rate of scavenging of the activator molecule (at a given
concentration of the latter) being proportional to the
concentration of the enzyme itself as well as to the
second power of the GSH concentration. It can thus
be expected theoretically that a high dietary LA/oleic
acid ratio, low Se intake and poor GSH status may
interact synergistically as causes of much 9- and
13-HODE production and hence much activation of
the vanilloid receptor (leading again to more intense
pain).
One should on this background not exclude the possi-
bility that the high prevalence of chronic pain conditions
found in the adult population in Norway may in part be
explained as a side effect of the recommendations given
by Norwegian health authorities (both to the general
public and to the food industry) to increase the intake
of LA in the general population by recommending that
the LA concentration in margarine should be high and
that people should consume LA-rich margarine and
vegetable oils in preference to butter and other fat from
animals other than fish. Thus, while it may be a matter
of debate whether a high intake of LA has helped to
reduce the incidence of ischemic heart disease or not,
there is now strong reason to believe that the recom-
mendations may have had an important (though wholly
unintended) negative side effect by enhancing the sever-
ity (and most likely also the prevalence) of chronic pain
problems in the adult population.
On the positive side, it should be noted that the 9-
HODE [169,170], 13-HODE [170] and the 13-HODE
metabolite 13-oxo-ODE [171] have been reported to
function as agonist ligands of the PPAR-gamma recep-
tor; however, it has also been reported that 13-(S)-
HODE up-regulates the MAP kinase signaling pathway
and subsequently down-regulates PPARgamma in
human colorectal carcinoma cells [172]. The same sub-
stance can thus have effects going in opposite directions,
as far as PPARgamma activation is concerned. Enhanced
PPARgamma stimulation would be expected to benefi-
cial in various disease situations, not only in diabetes
type 2 [82], but also in cardiac failure [173].
13-S-hydroxyoctadecadienoic acid has also been
reported to down-regulate PPAR-delta, which can in
turn lead to induction of apoptosis in colorectal cancer
cells [174]. It may thus be con c l u d e dt h a to x i d i z e dL A
metabolites can have favourable as well as unfavourable
effects in various disease conditions, and it is not easy
to find out, when talking about the health situation of
the population as a whole with many different diseases
(and perhaps not even for a single disease, such as can-
cer), whether the favourable or the unfavourable effects
should be considered the most important ones.
Prostaglandin overproduction because of poor diet can
lead to enhancement of pain and neurogenic inflammation
because of C-fibre hypersensitivity
Prostaglandin (PG) overproduction because of poor diet
(with too much AA and/or too little Se or too little
GSH precursor amino acids) leads to sensitization of the
C-fibres [90] to pain-inducing stimuli of all kinds
(including low extracellular pH and high concentrations
of 9- and 13-HODE). At the same time, it leads also to
enhanced release of proinflammatory peptides from the
C-fibres, which means intensification of almost any kind
of inflammatory reaction in C-fibre-innervated tissues,
including the skin, skeletal muscle, synovial membranes
and the mucosa of the upper and lower airways.
In ischemic pain conditions (including pain caused by
skeletal muscle spasms or static overload), one must
expect that there will be a synergistic interaction between
prostaglandin overproduction leading to C-fibre hyper-
sensitivity and enhanced lactic acid production in the
ischemic area, leading to enhanced acidic pH-mediated
[160] activation of the vanilloid receptor. The rate of lac-
tic acid production in a tissue area with limited oxygen
supply is limited by the availability of carbohydrate pre-
cursors (glucose or glycogen) entering the glycolytic
pathway. Since the quotient between rates of glucose and
oxygen diffusion into the hypoxic area must be directly
proportional to the blood sugar concentration, it must be
expected that higher blood sugar concentrations will lead
to more lactic acid production in ischemic or strongly
hypoxic areas, which means stronger activation of the
vanilloid receptors in these areas and hence more pain.
It must therefore be expected that there will be a
synergistic interaction between high blood sugar levels
(leading to enhanced vanilloid receptor activation) and
prostaglandin overproduction (leading to C-fibre hyper-
sensitivity) as causes of enhanced pain in all such com-
mon skeletomuscular disorders that are associated with
a tendency for abnormal static loads or muscle spasms
in the painful areas. A combination of overconsumption
of AA, suboptimal Se intake, high consumption of high
glycaemic load foods and little physical activity (which
means less rapid consumption of blood sugar by the
muscles) can not be favourable for the chronic pain
patient, and one of the best ways to help him would
p r o b a b l yb eal i f e - s t y l ei n t e r v e n t i o nw h e r ea l lt h e s ef a c -
tors can simultaneously be corrected. Considering what
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the western industrial countries (with a combination of
very high AA intake, high consumption of high glycae-
mic load foods and often far from optimal Se intake), it
should come as no surprise that the prevalence of
chronic pain problems in the adult population of many
of these countries is high.
Possible role of oxidative stress and impaired antioxidant
defense as causes of PKC-mediated C-fibre hypersensitivity
C-fibres can also be sensitized by activation of protein
kinase C (PKC) [90], and they contain several PKC iso-
zymes that can be activated by oxidative stress [90]. It is
therefore possible that Se or GSH depletion leading to
impaired scavenging both of H2O2, organic hydroperox-
ides and peroxynitrite inside the C-fibres could be
another important cause of C-fibre hypersensitivity,
leading to enhancement of pain sensitivity and neuro-
genic inflammation. It is also possible that enhancement
of the rate of reactive oxygen species (ROS) production
inside C-fibre mitochondria because of mitochondrial
DNA aging (natural or unnatural/pathologic, e.g. smok-
ing-induced or drug-induced) could have a similar effect
[90], with enhancement of mitochondrial ROS produc-
tion and impairment of the capacity of ROS-scavenging
enzymes interacting synergistically with each other as
causes of PKC-mediated C-fibre hypersensitivity and
hence more pain.
PKC is also activated by diacylglycerol (DAG) [82],
and it is possible that factors such as hyperglycemia
known to cause abnormal enhancement of the DAG
concentration and therefore activating PKC and NAD(P)
H oxidase in endothelial cells (as will be discussed later)
also could play a role as contributory causes of hyperal-
gesia mediated by C-fibre PKC. It has already been men-
tioned that hyperglycemia also must be expected to lead
to enhancement of lactic acid production in muscles
under conditions of severely restricted oxygen supply,
which will lead to enhanced stimulation of vanilloid
receptors. A double bonus may thus be expected if the
pain patient can change his diet and exercise more in
order to keep the blood sugar level better under control.
The practical significance of mechanisms leading to
C - f i b r eh y p e r s e n s i t i v i t yi ss u g g e s t e db yt h ef a c tt h a ta l l
conventional NSAIDs (non-steroidal anti-inflammatory
drugs) function as cyclooxygenase inhibitors (even
though this may not be their only mechanism of action)
[82]. These drugs are very commonly used for treatment
of acute as well as chronic diseases and injuries asso-
ciated with pain and inflammation. Their analgesic effect
can in large measure be explained as a result of reduced
PG production, probably both peripherally (leading to
less PG-induced sensitization of the C-fibres) and in the
central nervous system. None of the NSAIDs are with-
out side effects, which sometimes can be severe [82].
It should be noted that these drugs will most likely not
help to correct the problem of C-fibre hypersensitivity
caused by oxidative stress-mediated or DAG-mediated
activation of PKC. One should therefore expect that
they may have only limited effect in situations where
PKC-mediated C-fibre hypersensitivity is an important
part of the problem.
Dietary or other interventions for reducing oxidative
activation of PKC isozymes in C-fibres (by optimizing
the functions of C-fibre mitochondria and of their cellu-
lar system of antioxidant defense) must be expected to
affect other cell types as well and lead to reduction of
the synthesis of prostaglandins by leukocytes in the
painful areas (for reasons that have already been
explained above). A double bonus may thus be expected
for such interventions, when prostaglandin-mediated
and PKC-mediated C-fibre hypersensitivity can be
reduced simultaneously by enhancing the intake of anti-
oxidant nutrients or by using such hormones, such as
melatonin, or dietary hormone precursors (such as tryp-
tophan and vitamin D) that can help to enhance the
expression of antioxidant enzymes and/or improve the
function of dysfunctional mitochondria, at least in some
cell types and organs [122].
In skeletal muscle ischemic pain, a triple bonus may be
expected from the application of a suitable combination
of antioxidant nutrients and hormones, since there is
much research literature showing that several antioxidant
nutrients (including Se, GSH, taurine and carnosine) and
also melatonin at high dosage levels have substantial pro-
tective effects against damage caused by ischemia and
reperfusion both in the heart and several other organs
[154], including skeletal muscle (for some of the sub-
stances concerned, even though there are fewer experi-
mental studies of this kind on skeletal muscle than on
the heart, brain and liver). It goes far beyond the scope of
the present article to survey and give references to all
this literature, but much of it can easily be found on
PubMed by combining the appropriate search words
(e.g.: heart selenium ischemia protection).
While such methods for ameliorating skeletomuscular
pains should not be regarded as substitutes for conven-
tional physical therapy methods for treatment of the dis-
eases concerned (including a combination of muscle
relaxation therapy and physical exercise), there must be
good reason to expect that the physical therapy methods,
when effective, must synergize with dietary intervention
or endocrine treatment methods either for correcting
C-fibre hypersensitivity, for decreasing lactic acid pro-
duction in the muscles under severe hypoxia, or for
improving the function of the muscle cells under condi-
tions of restricted oxygen supply and protecting them
against damage caused by ischemia and subsequent
reperfusion. A combination of both forms of therapy
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inside and from the outside simultaneously) would be
expected, especially for the more difficult cases, to give
much better results than either applied alone. It must
also be expected that a combination both of internal and
external protection of vulnerable muscles must be better
than either method alone for effective prophylaxis at a
population level or for especially vulnerable groups (e.g.
music students and musicians).
Mechanism of action and side effects of acetaminophen: is
acetaminophen an important mitochondrial mutagen in the
brain?
The mechanism and sites of action of another com-
monly used analgesic drug (which is not considered an
NSAID because it does not have much antiinflammatory
effect), viz. acetaminophen (paracetamol) has been sub-
ject of much controversy; it has been suggested that it
might act by inhibition of a splice variant of COX-1 that
has been called COX-3 and that is expressed in the cen-
tral nervous system, but not peripherally [175]. More
recently, evidence has been presented that suggests acet-
aminophen may function as a selective COX-2 inhibitor
in humans [176].
It has earlier been proposed that acetaminophen can
function as a cyclooxygenase inhibitor by reduction of a
group at the active site of the enzyme that must be
oxidized for activity [177,178]. In a study from 2001 it
was found that reduced glutathione (GSH) and GPx
enhanced the potency of acetaminophen as an inhibitor
against both purified ovine COX-1 (oCOX-1) and human
COX-2 (hCOX-2) approximately 30-fold to give IC50
values of 33 microM and 980 microM, respectively [178].
Acetaminophen was found to be a good reducing agent
of both oCOX-1 and hCOX-2 [178]. These observations
were thought to be consistent with a mechanism of inhi-
bition in which acetaminophen acts to reduce the active
oxidized form of the cyclooxygenase to the resting form
[178]. Inhibition would therefore be more effective under
conditions of low peroxide concentration (when activa-
tion of the enzyme by oxidation takes place more slowly),
consistent with the known tissue selectivity of acetamino-
phen [178].
The poor anti-inflammatory effect of acetaminophen
that has been observed in most, but not all [179] studies
might then be explained as a result of the common ten-
dency for inflammatory processes to be attended by
high oxidative and sometimes also high nitrative stress
(especially in rodent models of inflammation, since
inducible NO synthase is expressed more easily in
rodent leukocytes than in human leukocytes), which
w o u l dl e a dt oah i g hr a t eo fC O Xa c t i v a t i o nb yo x i d a -
tion caused either by H2O2 [124,180], organic hydroper-
oxides [77,180] or peroxynitrite [125]. The reason why a
better anti-inflammatory effect was found in Skjelbred
and Løkken’s study [179] could perhaps be that they
used a model of inflammation (viz. the magnitude of the
inflammatory reaction following tooth extraction) that
conceivably might be associated with less oxidative
stress than most other common forms of inflammation.
More recent observations [181,182] seem to have con-
firmed the validity of Ouellet and Percival’s observations
[178], but a new mechanism of action for acetamino-
phen has also been discovered, viz. conversion into an
active metabolite (p-aminophenol), which is conjugated
with arachidonic acid by fatty acid amide hydrolase to
form a compound called AM404, which exerts an
analgesic effect through cannabinoid receptors [181].
Acetaminophen has been reported to be converted by
cyclooxygenases both through 1- and 2-electron oxidation
[177,183,184] into protein-reactive metabolites [185]. It is
a plausible hypothesis that the acetaminophen metabolites
that are formed by cyclooxygenases (especially the product
(s) of 1-electron oxidation) can be covalently bound to
DNA molecules as well and therefore might be mutagenic.
It is thus possible that the same redox reactions that
explain why acetaminophen can inhibit cyclooxygenases
[178] also may convert this drug into DNA-reactive
metabolites.
When health authorities all over the world started,
many years ago, to recommend acetaminophen to be
used, rather than acetylsalicylic acid (aspirin), as the first
choice drug for treatment of common pain conditions
and fever, one of the main reasons for this was the risk
of development of Reyes’ syndrome in children taking
aspirin [82], while acetaminophen was without this side
effect [82]. Another important reason was that the
observed death rate because of acute side effects was
clearly higher for aspirin (mainly because of severe gas-
tric haemorrhage) than for acetaminophen. The recom-
mendations to prefer acetaminophen rather than aspirin
as the first choice drug for treatment of ordinary (not
overly severe) pain and ordinary fever are understand-
able on background of what was known at the time
when they first were issued (at which time the genotoxi-
city of acetaminophen still was unknown). But it is
more difficult to understand why these recommenda-
tions were not changed after it had been reported,
already some 25 years ago [186], that acetaminophen is
mutagenic, which has later been confirmed by other
groups [187,188]. It has also been reported later that
acetaminophen interferes with DNA repair [189,190].
Acetaminophen itself does not react with DNA mole-
cules, but while much of it is conjugated and excreted
before oxidation [82], another part is oxidized by various
forms of cytochrome P450, including cytochrome
P4502E1 (CYP2E1). This process gives rise to the highly
reactive and toxic metabolite N-acetyl-p-benzoquinone
i m i n e[ 8 2 ] ,w h i c hi sp r e s u m a b l yo n eo ft h em o s t
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phen is metabolized in the liver or other organs. If the
reaction mechanism of CYP2E1-catalyzed acetamino-
phen oxidation is similar as for other and better studied
CYP2E1-catalyzed reactions, such as the CYP2E1-
catalyzed oxidation of alcohol [141,191], one must also
expect that CYP2E1-catalyzed oxidation of acetamino-
phen will be attended by formation of reactive oxygen
species (ROS), peroxynitrite and perhaps organic radi-
cals that also will be mutagenic.
N-acetyl-p-benzoquinone imine is detoxified by spon-
taneous reaction with reduced glutathione (GSH) [82].
One may then expect theoretically from diffusion and
reaction kinetics that the steady-state concentration will
decay quasi-exponentially as a function of distance from
the sites of production, with the decay curve being stee-
per when the intracellular GSH concentration is high
than when it is low. Cytochromes P450 are membrane-
bound enzymes that are found especially in the endo-
plasmic reticulum and the inner mitochondrial mem-
brane, even though they have been observed also in
other parts of the cells, such as the outer nuclear mem-
brane, different Golgi compartments, peroxisomes and
the plasma membrane [192]. For brain cells, it has been
reported that CYP2E1 is partly localized to the mito-
chondria [193,194].
The distance is evidently much shorter from the inner
mitochondrial membrane to mitochondrial DNA than
between the endoplasmic reticulum and nuclear DNA,
a tt h es a m et i m ea st h e r ea r en oo t h e rm e m b r a n e sh i n -
dering the passage of reactive acetaminophen metabo-
lites between the inner mitochondrial membrane and
the mitochondrial chromosomes (in contrast to the
situation for nuclear DNA, where a double membrane
hinders the diffusion of reactive acetaminophen metabo-
lites from the cytosol into the nucleus). There are also
no histones in the mitochondria, leaving the mitochon-
drial DNA much less protected against mutagenic mole-
cules compared with much of the nuclear DNA
(especially all such genes that are not actively expressed,
and also so-called junk DNA), that is well shielded
because of complex formation with histones and other
protein molecules in combination with multiple DNA
coiling. This coiling will sterically make it more difficult
for mutagenic molecules coming from the outside to get
access to the inner part of the coil. It is therefore good
reason to suspect that acetaminophen may be far more
mutagenic to mitochondrial than to nuclear DNA, at
least in the brain. An important, perhaps not adequately
studied question concerns the efficacy of repair mechan-
isms for acetaminophen-induced DNA lesions, other
than oxidative DNA damage, in the mitochondria com-
pared to the nucleus.
The connection between acetaminophen and asthma: is it a
consequence of mutagenic effects in mitochondria in the
lower respiratory tract?
More recently, it has been shown in epidemiological stu-
dies that the use of acetaminophen by children [195] or
by their mothers during pregnancy [196,197] is asso-
ciated with significantly enhanced risk of asthma or
other respiratory symptoms - which perhaps might be a
consequence of the mutagenic effects of this drug, espe-
cially for mitochondrial DNA, either in leukocyte pro-
genitors, C-fibres or other cell types in the lower
airways (such as smooth muscle cells or epithelial cells).
If it does not happen as a direct consequence of adap-
tive immunity (with acetaminophen functioning as an
allergen), which appears highly unlikely in this case, a
mutagenic effect is by far the most plausible mechanism
for explaining how the organism can “remember” expo-
sure to a drug over several years to account for long-
term (or permanent and irreversible) side effects.
Too much mutations in mitochondrial DNA must be
expected to lead to enhancement of the rate of mito-
chondrial ROS production [90], which may in turn lead
to enhanced expression not only of protective antioxi-
dant genes, but also of a large number of proinflamma-
tory genes that are positively regulated [198,199] by the
redox-regulated [128,198,199] transcription factors NF-
kappaB and AP-1. This can lead to enhanced expression
of many of those proinflammatory genes that are impor-
tant in asthma and other allergic diseases [199,200].
In the C-fibres, it must also be expected that
enhanced ROS production will lead to activation of sev-
eral isozymes of protein kinase C (PKC) that have been
found in C-fibres and are activated by oxidative stress
[90], at the same time as it is well documented that
PKC activation leads to sensitization of the C-fibres
[90]. One of the likely consequences of this will be
enhanced secretion of proinflammatory peptides from
C-fibres in the lower airways [154], while another possi-
ble consequence could be enhanced activity over a vagal
reflex arc causing secretion of acetylcholine from para-
sympathetic nerve fibres in the lower airways. This,
however, is a difficult and complicated topic since there
is evidence for differential reflex regulation of choliner-
gic and noncholinergic parasympathetic nerves innervat-
ing the lower airways - with different reflex pathways
associated with vagal nerves having opposite effects on
the tone of bronchial smooth muscle cells [201].
It may on background of the observations linking
acetaminophen both with mitochondrial DNA muta-
tions and asthma be good reason to ask, what would be
the more sensible strategy, either as now to correct pain
conditions resulting from prostaglandin overproduction
by highly liberal distribution of the mitochondrial
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adults, or to restrict the dietary intake of AA while
enhancing the intake of antioxidant nutrients such as
GSH/sulphur amino acids and Se (but also taurine, car-
nosine/anserine and polyphenolic plant antioxidants)
that hopefully might help to decrease cyclooxygenase
activation and COX-2 expression? Is it science-based
medicine when regulatory agencies and governments are
reluctant to draw what would appear to be the only nat-
ural conclusions from all those reports that have shown
that acetaminophen is mutagenic or that link it with
enhanced risk of asthma, while neglecting all those even
more numerous reports that show that it is harmful to
eat too little EPA + DHA and too much AA?
Prostaglandin biosynthesis, NSAIDs, COXIBs and cancer
COX-2 is expressed in many, but far from all tumour
cell populations, being especially common in colon can-
cer [202]. But tumours (even in such cases when the
tumour cells themselves don’te x p r e s st h i se n z y m e )d o
also contain other COX-2-expressing cell types, includ-
ing endothelial cells, where COX-2 is induced by the
proangiogenic factor VEGF, released by tumour cells
[203]. Tumour endothelial cells release COX-2-derived
PGH2, which can be transformed into PGE2 by PGE
synthase-expressing tumour cells [203]. PGH2 can also
be converted into PGI2 by the endothelial cells and to
TxA2 by platelets [82]. In vivo models of thromboxane
A synthase or PGI synthase overexpression indicate
proangiogenic effects for TxA2 and antiangiogenic
effects for PGI2 [203]. Since PGH2 functions as an ago-
nist ligand of the thromboxane A receptor (which is
often called the thromboxane/prostaglandin endoperox-
ide receptor), one must expect that PGH2 itself will help
to stimulate tumour angiogenesis, even without conver-
sion into TxA2 or PGE2. COX-2 can, moreover, also be
found in tumour-infiltrating leukocytes, such as macro-
phages, and may thus play an important role in tumour
biology even in many of those cases where the tumour
cells themselves don’t express this enzyme.
Overproduction of PGE2 in tumour cell populations
has a number of harmful effects, including stimulation
of tumour angiogenesis [203-206], i.e. enhancing the
ingrowth of blood vessels in the tumour, which will
enable the tumour to grow faster by improving both its
oxygen and nutrient supply (which normally are very
important for limiting tumour growth [207]). It also
suppresses the activities of various classes of leukocytes,
such as NK cells [208-210], lymphokine-activated killer
(LAK) cells [211] and CD8
+ T cells [212,213], that are
important for tumour cell killing [208,209,214,215].
PGE2 can, moreover, also inhibit tumour cell apoptosis,
at least in some tumour cell lines [216], if not necessa-
rily in all types of tumour cells.
At the same time, it should not be forgotten that the
above-mentioned anti-tumour immunological functions -
that overlap strongly with NK-cell- and T-cell-mediated
functions important for antiviral immunological defense -
also depend on the glutamine, tryptophan, GSH and
Se status of the patient [122,154,217]. As an example can
be mentioned that NK cells normally will secrete the
Th1-associated cytokine interferon-gamma following
simultaneous stimulation with interleukin-12 (IL-12) and
interleukin-2 (IL-2), provided that they are not GSH-
depleted [217]. But GSH-depleted NK cells will instead
secrete the Th2-associated (and Th1-inhibitory) cytokine
interleukin-10 (IL-10) following double stimulation with
IL-12 and IL-2 [217].
Epidemiological studies have shown that regular con-
sumption of traditional over the counter nonsteroidal
anti-inflammatory drugs (NSAIDs) or selective COX-2
inhibitors is associated with significant reduction of the
death risk not only from colon cancer, but also from
various other forms of cancer [218]. In a recent meta-
analysis, it was found that regular intake of over the
counter NSAIDs produced highly significant composite
risk reductions of 43% for colon cancer, 25% for breast
cancer, 28% for lung cancer, and 27% for prostate can-
cer [218]. Furthermore, it was found in a series of case
control studies that daily use of a selective COX-2 inhi-
bitor, either celecoxib or rofecoxib, significantly reduced
the risk for each of these malignancies [218]. The evi-
dence is now considered compelling that anti-inflamma-
tory agents with selective or non-selective activity
against cycloooxygenase-2 (COX-2) have strong poten-
tial for the chemoprevention of deaths from cancers of
the colon, breast, prostate and lung [218].
The question can be raised to what extent the
observed effect on death risk from cancer following use
of either nonselective NSAIDs or COXIBs might be a
consequence of primary chemoprevention because of an
antimutagenic effect of COX-2 inhibition (i.e. inhibition
of the appearance of the first malignant cells that later
can give rise to a tumour cell population), and to what
extent the death risk reduction might instead be
explained as a consequence of delayed progression of
the disease after it has started. From what is known
about effects of prostaglandins in cancer, as well as
about COX-2 itself (since COX-2 is an enzyme that can
also oxidize other substrates than polyunsaturated fatty
acids, and some of the products of such reactions could
be mutagenic), it must be judged most reasonable to
believe that the main effect could be on the rate of pro-
gression of the disease (because of poorer angiogenesis,
higher tendency for apoptosis among the tumour cells
and better antitumour immunity) rather than an anti-
mutagenic effect leading to primary chemoprevention. If
this conclusion is correct, it would obviously have
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forms of cancer where COX-2 is expressed in the
tumour cells (which should now be easy to find out
from biopsy studies), since there is no reason to believe
that the delaying effect of COX-2 on disease progression
should be restricted to the earliest stages of develop-
ment of the disease.
Can a better diet enhance the therapeutic effect while
reducing the risk of adverse side effects for COXIBs
during therapy of rheumatoid arthritis and cancer?
It is probably much better to limit the production of
prostaglandins in a tumour cell population by a combi-
nation both of dietary and pharmacological intervention
rather than by pharmacological intervention alone, since
with such combinations, it should be possible to obtain
the same proportional reduction of prostaglandin bio-
synthesis in the tumours with much less side effects
than with pharmacological intervention alone. With less
side effects, it is also possible to enhance the intensity of
treatment (i.e. aim for a larger proportional reduction of
PG synthesis inside the tumour than one could have
done with pharmacological therapy alone). It should
therefore be considered mandatory for all cancer
patients, especially in such cases where the tumour cells
express COX-2 or COX-1, to restrict the dietary intake
of AA, at the same time as the total intake of other
unsaturated fatty acids (especially omega-3 fatty acids
and oleic acid) that compete with AA for incorporation
in the same positions in the membrane lipids of the
tumour cells should be increased. Given the important
role of COX-2 expression also in other cell types in the
tumours, such as endothelial cells [203] and macro-
phages, these guidelines may be expected to be thera-
peutically useful even in a majority of such cases when
the tumour cells themselves don’t express either COX-2
or COX-1.
The patients should, moreover, also be advised to
enhance the dietary intake of such antioxidant nutrients
(e.g. Se and GSH, or GSH precursors, but also such
plant oxidants that have been reported to have similar
effects) that hopefully may help to reduce COX-2
expression and activation in the tumour cell population,
tumour-associated macrophages and tumour endothelial
cells. These antioxidant nutrients can in any case (even
if they should not be effective for reducing prostaglandin
synthesis in the tumour cells) not be expected to have
any harmful side effects, but may rather help to improve
the overall health and quality of life for the patients, e.g.
by helping to maintain muscular strength, reduce the
risk of cardiovascular complications [122], and
strenghten immunological functions [122,154,217].
Observations confirming that COX-2 blockade is
effective for cancer prevention have been tempered by
observations that some selective COX-2 inhibitors pose
a risk to the cardiovascular system [218]. Nevertheless, a
meta-analysis of independent estimates from 72 studies
provides no evidence that the selective COX-2 inhibitor,
celecoxib, influences the relative risk of cardiovascular
disease (composite relative risk = 0.98, 95% CI = 0.88-
1.10) [218].
It is commonly assumed that the main reason why
traditional, non-selective NSAIDs can have sometimes
severe gastrointestinal side effects is inhibition of COX-
1 in the stomach [83]. One might then ask the question:
why does not the same happen - when the rate of EPA
oxidation by COX-1 is only 10% of the rate of AA oxi-
d a t i o nb yt h es a m ee n z y m e[ 7 6 ]-a l s ow h e no n e
reduces eicosanoid biosynthesis via COX-1 by reducing
the AA/(EPA + DHA) ratio of the diet? One possible
answer could be much higher local drug concentration
(because of local absorption) in the gastric mucosa fol-
lowing ingestion of the drug (but also in the mucosa of
the upper intestine), compared to the rest of the body
following absorption in the intestine (and transport
away from the intestine by the blood). Something simi-
lar can not happen following ingestion of phospholipids
and triglycerides containing long-chain polyunsaturated
fatty acids.
Selective COX-2 inhibitors (COXIBs) have been
shown to possess much improved gastrointestinal toler-
ability with reduction of the incidence and/or severity of
gastrointestinal adverse events, when compared with
nonselective inhibitors (that also inhibit COX-1) [83].
An unexpected cardiovascular toxicity did, however,
emerge during COXIBs post marketing outcome studies
[83]. This COXIB-associated cardiovascular toxicity has
multiple manifestations, which include the induction of
myocardial infarction, oedema, thrombosis, blood pres-
sure destabilization and death [83]. It has led to with-
drawal from the market of two of the drugs concerned,
viz. rofecoxib and valdecoxib, while celecoxib is still in
the market because the risk of cardiovascular side effects
of this drug is significantly less than for those that have
been retracted [83].
It has been thought that the cardiovascular side effects
of COXIBs may in large measure be explained as a
result of COX-2 inhibition in endothelial cells, leading
to a disturbance of the balance between prostacyclin
synthesis in the endothelial cells and thromboxane
synthesis in the platelets [81]. The thromboxanes (TxA2
and TxA3) are potent platelet aggregators and vasocon-
strictors [82], while the prostacyclins (PGI2 and PGI3)
are potent anti-aggregators and vasodilators [81,82].
Although COX-2, in contrast to COX-1, has often been
regarded as an inducible enzyme that only has a role in
pathophysiological processes like pain and inflammation,
experimental and clinical studies have shown that
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the kidney and also in vascular endothelium, where it
executes important physiological functions and is
needed for the maintenance of vascular integrity [81].
Prostacyclin is formed to a significant extent by COX-2,
and its levels are reduced to less than half of normal
when COX-2 is inhibited by COXIBs [81].
But the prostacyclin/thromboxane balance is also
heavily influenced by the dietary AA/(EPA + DPA +
DHA) ratio. A high dietary AA/(EPA + DPA + DHA)
ratio enhances the risk of thrombotic events, while a
low dietary AA/(EPA + DPA + DHA) ratio has the
opposite effect, as first shown by the studies of Dyerberg
and collaborators on Inuits in Greenland [219]. This was
earlier explained by the assumption, now shown to be
f a l s e[ 7 6 ]t h a tT x A 3 (that is formed from EPA) is inac-
tive, whereas the prostacyclin PGI3 (that is also formed
from EPA) is fully active. Now another explanation
must be sought instead of the false assumption that
TxA3 is inactive. Part of this new and hopefully more
correct explanation can probably be found in the differ-
ent substrate specificities for COX-1 compared with
COX-2, with the rate of AA conversion to PGH2 by
COX-1 being 10 times higher than the rate of EPA con-
version to PGH3 by the same enzyme, whereas the dif-
ference between the rates of oxidation of AA and EPA
b yC O X - 2i sm u c hs m a l l e r[ 7 6 ] .E n h a n c e m e n to ft h e
dietary EPA/AA ratio will therefore affect the rate of
prostacyclin synthesis in the endothelium less than it
affects the rate of thromboxane synthesis in the plate-
lets. Also, when EPA is a better inhibitor of AA oxida-
tion by COX-1 than for AA oxidation by COX-2 [76],
this means that it will inhibit TxA2 synthesis in the pla-
telets more than it inhibits PGI2 synthesis in the
endothelium - which is another mechanism acting in
the same direction. DHA, with 22 carbon atoms and 6
double bonds, is not a precursor for prostaglandin or
thromboxane biosynthesis. But it functions as a compe-
titive inhibitor for the oxidation of polyunsaturated fatty
acids with 20 carbon atoms in the platelet cyclooxygen-
ase reaction and therefore as an inhibitor of the bio-
synthesis of thromboxane A2 [220].
Docosapentaenoic acid (DPA) has been reported to
function as a potent inhibitor of platelet aggregation
[220]. This can most likely be explained as a conse-
quence of the same effect that EPA and DHA also have
as inhibitors of platelet aggregation caused by TxA2 or
stable TxA2 analogs because they bind to the platelet
thromboxane A2/endoperoxide receptor, where they
function as blocking agents [221-223]. DHA was found
to be more potent than EPA in blocking platelet aggre-
gation induced by the stable thromboxane A2 mimetic,
U46619 [221]. Prostaglandin endoperoxides, which are
very short-lived, can also function as agonists at the
receptor for thromboxane A2, which is therefore called
the thromboxane A2/prostaglandin H2 receptor [221] or
the prostaglandin-endoperoxide/thromboxane A2 recep-
tor [223]. When AA is metabolized much faster than
EPA by platelet cyclooxygenase, this will, of course, not
only lead to faster synthesis of thromboxanes, but to fas-
ter synthesis of PGH as well.
But in tumours where the tumour cells release much
VEGF leading to enhanced expression of COX-2 in the
endothelium and enhanced release of PGH from
endothelial cells [203], one must expect that a reduction
of the intake of AA while enhancing the intakes of EPA
and DHA will also help to reduce the release of PGH2
and of total PGH from the tumour endothelial cells
(even though the effect of reducing the intake of AA
and enhancing the intakes of EPA and DHA is not
equally large for COX-2-mediated synthesis of PGH2 in
the endothelium as it is for TxA2 synthesis in the plate-
l e t s ) .A tt h es a m et i m ei tm u s tb ee x p e c t e dt h a tE P A
and DHA will help to suppress the proangiogenic effect
that must be expected to occur for PGH2 coming from
the endothelium, similarly as for TxA2 coming from the
platelets [203], since PGH2 is an agonist ligand of the
thromboxane A2/prostaglandin H2 receptor [221], while
EPA and DHA function as blockers of this receptor
[221-223]. Reducing VEGF-mediated angiogenesis by
decreasing the intake of AA and enhancing the intakes
of EPA and DHA is a principle that could presumably
be useful also for the therapy of other diseases, where
overproduction of VEGF is an important part of the
pathogenetic mechanism (such as the neovascularisation
of eye tissues that may happen as a complication of
diabetes).
The rate of prostacyclin synthesis in the endothelium
depends not only on the dietary AA/(EPA + DHA) ratio,
but is also strongly influenced by the rate of reactive oxy-
gen species (ROS), peroxynitrite and PUFA hydroperox-
ide production in the endothelial cells, as well as by the
capacity of enzymes scavenging superoxide anion radical,
organic hydroperoxides and peroxynitrite. This is because
prostacyclin is irreversibly inhibited by low concentra-
tions of peroxynitrite [224] and certain products of lipid
peroxidation, including oxidized LDL [225,226].
Inhibition of prostacyclin synthetase in the endothelial
cells must, however, be expected to have doubly harmful
effect because it will not only lead to reduced synthesis
of prostacyclin, but also to enhancement of the rate of
PGH release from the endothelial cells when PGH is
not converted at a normal rate to prostacyclin - with
PGH2 functioning as a prostacyclin antagonist because
it is an agonist ligand of the thromboxane A2/prosta-
glandin H2 receptor [221]. It is therefore plausible to
speculate that the substantial VEGF-induced release of
PGH2 that has been observed in tumour endothelial
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VEGF induction of COX-2 [203], but also because pros-
tacyclin synthetase in the endothelial cells is simulta-
neously inhibited. It might furthermore be speculated
that this might happen not only because of the effect of
VEGF itself on rates of superoxide anion radical and
peroxynitrite production in the endothelial cells, but
also because of other sources of superoxide anion radi-
cal that can be converted into peroxynitrite in the
tumour microenvironment, which might include not
only activated phagocytes, but in a number of cases also
the tumour cells themselves.
Peroxynitrite is formed in a very fast reaction between
NO and superoxide anion radical [227]. The rate of per-
oxynitrite formation in the endothelium will thus be
enhanced when the rate of production of superoxide
anion radical - from endothelial NAD(P)H oxidase
[228-230], by decoupling of endothelial NO synthase
[231] and by leakage of electrons from the respiratory
chain in the mitochondria [230,232] - is high. One
must, moreover, also expect that the rate of peroxyni-
trite formation in the endothelium will be enhanced
when the activity of one or both superoxide dismutases
(one Cu/Zn-dependent and one Mn-dependent) in the
endothelial cells is depressed, as can happen, at least in
other cell types, as a consequence of copper deficiency
[233] or manganese deficiency [234].
T h er a t eo fs u p e r o x i d ea n i o nr a d i c a lp r o d u c t i o nb y
endothelial NAD(P)H oxidase can be enhanced i.a. by
hyperglycaemia [228,229], by advanced glycation end
products (AGEs) [230], by free fatty acids [228], and by
angiotensin II [235], while the rate of superoxide anion
radical production in the mitochondria of endothelial
cells is enhanced i.a. by AGEs [230], by TNF-alpha
[232], and very likely also by mitochondrial DNA aging
(i.e. the progressive accumulation of mitochondrial DNA
mutations as a function of age), similarly as is known for
other cell types [90,236]. The effect of hyperglycemia on
superoxide anion radical production by the endothelial
NAD(P)H oxidase is mediated by enhanced production
of diacylglycerol (DAG) in the endothelial cells, with
DAG activating PKC [228]. It might be speculated, as
earlier mentioned, that a similar hyperglycemia-induced
enhancement of DAG synthesis also could play a role as
one of the causes of hyperalgesia when it occurs in
C-fibres.
Endothelial NO synthase uncoupling happens as a
consequence of undersaturation of the enzyme with the
cofactor 5,6,7,8-tetrahydrobiopterin [231], which can in
turn happen as a consequence of too rapid oxidative
degradation of this cofactor and accumulation of its oxi-
dation product 7,8-dihydrobiopterin [231]. Endothelial
dysfunction happening at least in part as a consequence
of uncoupling of endothelial NO synthase is a very
common complication of several different conditions
that are associated with enhanced oxidative stress and/
or impaired antioxidant defence in blood plasma and/or
in the endothelium, including diabetes [237-239], hyper-
tension [238], hypercholesterolemia [238], and chronic
smoking [238].
It can be seen that there is a surprising degree of
overlap between the etiopathogenesis of cardiovascular
diseases and pathophysiological processes controlling
the rate of tumour angiogenesis in cancer patients (by
inhibiting the synthesis of antioangiogenic prostacyclin
and enhancing the release of proangiogenic prostaglan-
din endoperoxides from tumour endothelial cells). Many
of the same therapeutic interventions that may be bene-
ficial for patients with cardiovascular diseases might
hence be useful also for patients suffering from cancer.
Release of NO from tumour cells expressing inducible
NO synthase (NOS-2) can also be expected to play a
role in this context by contributing to enhancement of
the rate of peroxynitrite production both in blood
plasma and inside the endothelial cells, especially when
the production of superoxide anion radical from various
sources is high. When this leads to enhanced uncou-
pling of endothelial NO synthase (because of enhanced
destruction of 5,6,7,8-tetrahydrobiopterin by peroxyni-
trite), it means that there will be more production of
superoxide anion radical inside the endothelial cells,
with the combination of NO coming from the tumour
cells and superoxide anion radical coming from
uncoupled endothelial NO synthase being a very effec-
tive method for inhibiting prostacyclin synthetase by
peroxynitrite, so that the production of antiangiogenic
[203] prostacyclin will be reduced at the same time as
endothelial cell release of proangiogenic [203] PGH2 is
enhanced. It is not unreasonable to speculate that this
mechanism of stimulating tumour angiogenesis might
be one of the most important reasons why expression of
NO synthase-2 can give tumour cells a Darwinian fit-
ness advantage, and why it can often be difficult to treat
tumours expressing this enzyme (even though NO over-
production has multiple effects both harmful and benefi-
cial for the tumour cells, with the net effect apparently
being different in different forms of cancer). It might be
well worth to test the effect of 5,6,7,8-tetrahydrobiop-
terin supplementation (in an attempt to normalize the
function of uncoupled endothelial NO synthase
[ 2 3 7 , 2 3 9 ] )a sp a r to ft h et h e r a p y ,e.g. in colon cancer
when the tumour cells express NOS-2.
Peroxynitrite and water-soluble organic hydroperox-
ides are scavenged by various enzymes including the
selenoproteins GPx-1 [126,127] and selenoprotein P,
and also some of the peroxiredoxins [227,240,241]. GPx-
1 uses reduced glutathione (GSH) as its reducing cofac-
tor, displaying tert-uni ping pong kinetics [126]. For a
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or peroxynitrite), the rate of scavenging of the oxidizing
substrate will thus be determined by the product of the
concentration of the enzyme (which depends on Se sta-
tus) and the second power of the GSH concentration.
The combined effect of all the above-mentioned fac-
tors that can influence the balance between PGH release
from endothelial cells plus thromboxane production in
the platelets on one side and prostacyclin production in
the endothelium on the other side is most likely much
higher, especially if several of these factors act simulta-
neously in the same direction, than that of selective
COX-2 inhibitors at recommended dosage levels, even
when compared to those that have now been retracted
from the market. The conclusion can be drawn that it
most likely may be harmful to use selective COX-2 inhi-
bitors (especially those that have now been retracted
from the market) if nothing is done to correct such
other factors that may contribute to dangerous imbal-
ance of the ratio of thromboxane production in the pla-
telets to prostacyclin production in the endothelial cells.
B u ti ts h o u l dm o s tl i k e l yn o tb ed i f f i c u l tt ou s ed i e t a r y
therapy (by simultaneously reducing the dietary AA/
(EPA + DHA) ratio, improving the capacity of antioxi-
dant enzymes in blood plasma and the endothelium and
correcting NO synthase uncoupling) for decreasing to a
very significant extent the cardiovascular risk associated
with COXIBs, even the most dangerous ones. Such diet-
ary interventions must at the same time also be
expected to reduce the proangiogenic effect of VEGF
released from tumour cells because they may help to
reduce the rate of VEGF-induced release [203] of PGH2
from tumour endothelial cells (and in the case of EPA
and DHA reduce its proangiogenic effect by blocking
the thromboxane/prostaglandin endoperoxide receptor)
while in the case of antioxidant nutrients also enhancing
the production of antiangiogenic prostacyclin.
A tt h es a m et i m e ,i ti si m p o r t a n te n o u g ht ob e
repeated that some of the dietary interventions that can
be used for improving the thromboxane/prostacyclin
balance will synergize with the COXIBs as causes of
reduced prostaglandin production both in COX-2-
expressing tumour cells, tumour-infiltrating [207]
macrophages and tumour endothelial cells. The thera-
peutic ratio for the COXIBs can thus be improved
because of simultaneous improvement of the therapeutic
effect and reduction of the risk of harmful side effects,
compared to the use of similar doses of COXIBs alone
without simultaneous dietary intervention. This must be
expected to be the same both when COXIBs are used
for cancer therapy and when they are used for treatment
of non-infectious inflammatory diseases, such as rheu-
matoid arthritis, psoriatic arthritis or Bekhterev’s disease
(ankylosing spondylitis).
For highly lethal diseases such as cancer, one should,
of course, compare the risk of lethal cardiovascular side
effects of a drug with the protection against dying from
the disease itself (or from common complications to it)
that the same drug can give. With a combination of
optimal dietary intervention and COXIBs, it is reason-
able to expect that the risk of dying from cardiovascular
side effects of the drug (measured as the statistically
expected average shortening of survival) will be almost
negligible compared with the therapeutic benefit, con-
sidering the statistically expected average prolongation
of the time of survival before the patient will die from
his cancer. It is possible that this might apply even to
those COXIBs that now have been retracted from the
market, even though it might be more prudent to avoid
them.
Given the role of COX-2 expression not only in
tumour cells (in many, but far from all cancer patients),
but also in tumour endothelial cells [203], as well as in
tumour-infiltrating leukocytes, it would be expected that
the proposed combination of dietary intervention with
COXIBs might be therapeutically useful for a vast
majority of cancer patients, and not only for such cases
where the tumour cells express COX-2, although it
might be especially important for them. This might even
more be the case if this form of combined dietary/phar-
macological therapy is combined with such dietary or
pharmacological interventions that can help to reduce
the production or reduce the effect (by using drugs to
block the relevant receptors) also of substances other
than PGE2 (such as lactic acid, adenosine and TGF-
beta) that are commonly produced by tumour cells as
anti-immunological defense weapons. Even better results
might presumably be obtained by combining multifac-
torial therapies for suppressing tumour angiogenesis and
tumor antiimmunological defense with such therapies
that aim at specific or non-specific stimulation of antitu-
mour immunological defense, e.g. using tumour vaccines
or such hormones (e.g. melatonin at high dosage levels)
that help to stimulate those parts of the immune system
that are especially important for antiviral [90,154], anti-
tuberculosis and anticancer immunological defense.
It may be important to recognize that there is very
broad overlap between the immunological defense
methods used against viral infections, against infections
with bacteria living intracellularly (e.g. tuberculosis) and
against cancer, with NK cells and cytotoxic T lympho-
cytes being important in all these cases. It is an impor-
tant consequence of this that there can be substantial
overlap between antiimmunological defense methods
used by tumour cells and those used by some of the
bacterial pathogens, with tuberculosis (TB) probably
being the best example (especially when considering the
use of lactic acid as an antiimmunological defense
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much overlap comparing those metabolic changes that
always happen as a consequence of infectious disease
[135] and those happening in many cancer patients.
These metabolic disturbances can lead not only to
protein-energy malnutrition [135] (e.g. in AIDS and
tuberculosis patients, and in form of cancer cachexia
[133,134]), but also to various specific forms of malnu-
trition [135] (e.g. tryptophan, sulphur amino acid and
GSH depletion [122,131,132]), leading in turn to further
depression of antiviral [90,122,154,217], antibacterial
[135,217] and antitumour immunological defense. At
the same time it must also be expected that depletion of
GSH or other antioxidant nutrients in the malnourished
patient will lead to enhancement of COX-2 expression
and the rate of prostacyclin synthetase inactivation in
tumour endothelial cells, which means enhancement of
the rate of PGH2 release from the latter [203] and more
PGH2-induced and PGE2-induced (when the tumor cells
express PGE synthase [203]) stimulation of tumour
angiogenesis. All this means that much of the clinical
experience that has been obtained with non-specific
methods of immunostimulation for treatment of cancer
patients (e.g. using high-dose melatonin, or agonists of
Toll-like receptors) and regarding the role of nutrition
in cancer patients also might be relevant for treatment
of severe infectious diseases, such as tuberculosis, AIDS
and hypervirulent avian influenza [154], and vice versa.
Similarly, one must also expect that much of the knowl-
edge obtained from animal experiments, clinical obser-
vations and epidemiological ones about the importance
of nutrition factors and hormones for morbidity and
lethality in viral and bacterial infections [90,135,154]
may be highly relevant in cancer therapy as well. Better
contact and collaboration than is common today in the
fields of clinical nutrition and immunotherapy between
clinical scientists working with cancer and those work-
ing with serious infectious diseases, such as tuberculosis
and AIDS, could probably be most useful for both part-
ners as well as for their patients.
Epidemiological data concerning health benefits of fish
consumption and/or high intake of long-chain omega-3
fatty acids
Several epidemiological and other studies suggest (even
though the data are not completely consistent and
unequivocal) that fish and also fish oil consumption in
form of dietary supplements have marked protective
effects against cardiovascular deaths, especially in form
of sudden cardiac death (that may often happen as a
consequence of malignant arrhythmia) [242-244]. How-
ever, interpretation both of the epidemiological data and
the clinical intervention studies is fraught with pro-
blems, since marine fish does not only contain EPA and
DHA, but also biodegradation-resistant organic environ-
mental pollutants and toxic heavy metals (especially
mercury) [51,245,246], as well as several other nutrients
that either are known for certain to be cardioprotective
or hypothetically might be so, such as Se [51,247-250],
GSH and GSH precursor amino acids [251,252], anser-
ine [253-255], vitamin B12 [256] and taurine [9-12,257] -
and perhaps even arsenic (As) [51] in form of non-toxic
organic compounds [258], since it has been reported
that experimental As deficiency in animals can cause
development of a cardiomyopathy histologically very
similar to cardiomyopathy caused by Se deficiency [258].
Epidemiological data suggest also that the method of
food preparation plays an important role, with some
types of fried fish apparently being harmful [259,260],
most likely because of production of toxic substances
during food preparation either as a result of oxidation
or because of exposure to high temperature. For inter-
vention studies using fish oil capsules, one can not
always be certain about the quality of the product that
was used, i.e. whether the fish oil could have been oxi-
dized or not. It would not be surprising if oxidized fish
oil might have completely different physiological, phar-
macological or toxic effects compared to fish oil as such.
A preliminary conclusion may be drawn from some of
the studies concerned that EPA and DHA can protect
against sudden cardiac death because they have a
marked antiarrhythmic effect and therefore can protect
against malignant arrhythmia [242,244,261]. It is possi-
ble that this effect is exerted mainly by EPA and DHA
in form of free fatty acids rather than as eicosanoid
metabolites, most likely as a consequence of binding to
calcium and sodium channels in the cardiomyocytes
[262,263].
Is it possible to change poultry and pork meat to become
more health-promoting than now?
It has been proposed that the combined effect of dietary
intake of EPA and DHA and a number of other factors
determining levels of EPA and DHA in an individual can
best be assessed as the omega-3 index, defined as the
sum of relative concentrations of EPA and DHA in red
cells, and analyzed in a standardized fashion [69]. A very
recently published review of the literature, expanded by
measurements of the omega-3 index, indicates that the
risk of sudden cardiac death correlates inversely with the
omega-3 index [69]. For persons with an omega-3 index
<4%, the risk is tenfold higher, as compared to persons
with an omega-3 index >8% [69]. If this conclusion is
valid, it is difficult to see that there can be any method
more effective - and more cost-effective - for reducing
the rate of sudden cardiac death in entire populations
(e.g. in all of the United States, or in all of Russia), other
than imposing new regulatory requirements both on
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tory that meat products, offal and eggs shall not have
an AA/EPA + DHA) concentration ratio higher than,
say, 2/1.
Optimizing the omega-6/omega-3 ratio and Se
concentration of meat and eggs is better from an
ecological point of view than encouraging enhanced global
consumption of already overexploited fish resources
We think that all chicken meat as well as pork meat and
eggs available for human consumption should have a
favourable ratio between omega-6 and omega-3 fatty
acids, especially when considering the long-chain ones
such as AA, EPA and DHA. An important reason for
this is that the currently exploited sources of the long-
chain omega-3 fatty acids EPA, DPA and DHA are lim-
ited because of ecological limitations on total fish pro-
duction in the sea and a tendency for overexploitation
of many of the commercially most important fish stocks
[264]. Every step towards increasing the concentration
of these fatty acids in the regular human diet from
sources other than fish may therefore be of importance,
if it shall be possible to stop current overfishing and
prevent that important fish stocks or even species (e.g.
among tunas and sharks) shall go extinct in the near
future, as may perhaps already have happened with that
subpopulation (or subspecies) of cod that used to live
on the Newfoundland Banks.
Another important reason for not encouraging the
populations in Western Europe and North America to
eat more fish than they already do is that fish tradition-
ally has been very important for improving the nutri-
tional quality of the diet for people living in many parts
of Asia (such as Bangladesh) and Africa, not only as a
source of protein and essential amino acids (such as
lysine, tryptophan and the sulphur amino acids), but
also (especially when whole fish products like dried
kapenta are eaten) for nutrients such as calcium, iron,
zinc, Se, iodine, long-chain omega-3 fatty acids, nucleo-
tides and vitamin B12 [265]. But this important resource
is now becoming increasingly scarce (i.a. as a conse-
quence of local human population growth, but also as a
result of other factors, such as heavy local pollution,
overfishing, or diversion for the export market of fish
resources that earlier were consumed locally), especially
for the poorer part of the population living in those
countries. And when global resources of wild fish are
limited, it would be better if as much as possible of this
limited resource could go to those who have the largest
nutritional requirements because they can not afford to
eat other animal foods, rather than to the rich man’s
table.
Fish is also one of the best dietary sources of Se [51],
but it is neither difficult nor expensive to modify the feed
composition of domestic animals living on land, so that
the Se/protein concentration ratio in meat, offal, milk
and eggs can be made equally as high as for fish products.
The concentration of Se in wheat grown in Norway is
low (wheat grown at Norwegian University of Life
Sciences, Ås, Norway contains less than 20 microgram
Se/kg wheat, own results), mainly as a consequence of
poor bioavailability of soil Se for uptake in the plant
roots. The commercial chicken feed concentrate is there-
fore supplemented with Se to avoid Se deficiency in the
animals, which is given in form of inorganic Se (sodium
selenite). There are dual benefits from the Se supplemen-
tation: improved health and performance of the animals
and improved product quality for human consumption,
with increased Se concentration and decreased drip loss
during meat storage [266]. However, much of the Se
added to the feed concentrate as sodium selenite is
excreted and not incorporated into the meat. Supplemen-
tation of the feed with Se-enriched yeast or seleno-
methionine is much more efficient if the intention is not
only to prevent Se deficiency diseases in the animals, but
also to increase the Se concentration in meat for the ben-
efit of the human consumer [20,267,268].
As Se is a very scarce trace element on our planet and
total resources of commercially exploitable sulphide ores
containing Se are limited, the Se concentration in the
human diet should be increased in an efficient and sus-
tainable way with as little waste as possible [268]. Se sup-
plementation regimes in feed should therefore be
evaluated for sustainability, and organic Se forms that may
help to reduce overall waste should be preferred [268].
Could specifically tailored “functional food” meat be made
for use in cancer therapy?
Meat products containing a favourable ratio between
omega-6 and omega-3 fatty acids, an AA concentration
considerably less than now and high Se levels might be
desirable both for prophylactic reasons (in order to
reduce morbidity and mortality from several important
diseases in the general population) and for making it
practically more easy to optimize the composition of the
total diet for patients suffering from serious diseases
such as cancer, coronary heart disease, rheumatoid
arthritis, tuberculosis or HIV disease. For some of the
patient groups concerned (e.g. patients suffering from
colorectal cancer or rheumatoid arthritis), it would
probably be useful to make specifically tailored func-
tional food products that have especially high Se con-
centrations and AA as low as possible.
It has recently been reported that milk from cows fed
diets enriched with Se-enriched yeast may have a more
beneficial impact on bowel cancer compared to other Se
supplements [269]. It might be speculated that this did
not happen because Se from milk is more bioavailable
than Se from yeast, but because of a synergistic interac-
tion between Se and other antioxidant nutrients also
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acid and sulphur amino acids. More specifically, it might
be speculated that one of the mechanisms involved could
have been a combination of oleic acid-induced suppres-
sion of superoxide anion radical in the endothelial cells
[73], leading to reduction of the production of peroxyni-
trite, and improved scavenging of peroxynitrite by
glutathione peroxidase [127] in the endothelial cells
because their GSH concentration was enhanced. The
combination of less rapid production and more rapid
scavenging of peroxynitrite would have led to reduction
of peroxynitrite-mediated inhibition of prostacyclin
synthetase [224], leading in turn to reduction in the
release from endothelial cells of proangiogenic [203]
PGH2 and enhanced release of antiangiogenic [203] PGI2.
But if this explanation for the experimental observations
concerned should indeed be the correct one, something
similar would also be expected when we use Se-rich,
oleic acid-rich and AA-poor chicken meat as a source of
Se for cancer patients, rather than only using Se pills.
This will, of course, be especially important in patients
in whom the rate of sulphur amino acid catabolism is
enhanced because they suffer from protein catabolic
conditions, as has been demonstrated both in cancer
and HIV disease [131,132]. This seems to happen mainly
as a result of enhanced degradation of sulphur amino
acids to sulphuric acid in skeletal muscle [132], very
likely as a result either of cytokines (such as TNF-
alpha) [90,122], proteolysis-inducing factor (PIF) coming
from tumour cells [134], or other signal substances
enhancing the rate of reactive oxygen species (ROS)
production in the muscle cells. Enhancement of the
rates of superoxide anion radical, peroxynitrite and
H2O2 production in the muscle cells may conceivably
lead to enhancement of the rate of irreversible hyperoxi-
dation of sulphur atoms in cysteyl groups in protein and
glutathione and perhaps also of sulphur atoms in pro-
tein methionyl groups (i.e. oxidation of the sulphur
atoms in thiol or methionyl groups to an oxidation
number where the oxidative lesion can no longer be
repaired by enzymes such as thioltransferase, thiore-
doxin and methionine sulfoxide reductases).
It must be expected that many cancer patients, espe-
cially among those suffering from cancer cachexia (which
may affect up to 50% of cancer patients [133]), will be
depleted in GSH, which next must be expected to lead
not only to enhancement of the total rate of prostaglan-
din biosynthesis for reasons that have earlier been
explained, but also to enhanced peroxynitrite-mediated
inhibition of prostacyclin synthetase and enhanced
release of proangiogenic PGH2 from tumour endothelial
cells. This must in turn be expected to lead to enhanced
stimulation of tumour angiogenesis by PGH2 and PGE2
(and hence faster tumour growth), enhanced suppression
of leukocytes important for antitumour immunological
defense (such as NK cells, LAK cells and cytotoxic CD8
+
cells) by PGE2, and more eicosanoid-induced pain at the
s a m et i m ea st h e r em i g h tc o n c e i v a b l ya l s ob ee x a c e r b a -
tion of pain as a consequence of more oxidative activa-
tion of PKC isozymes in the C-fibres [90]. At the same
time, it can also be expected that GSH depletion will
change the pattern of cytokine secretion from NK cells
and other cell types towards reduction of the secretion of
Th1-associated cytokines, such as IL-12 and interferon-
gamma [154,217], and more secretion of Th2-associated
cytokines, such as IL-10 [217]. But changing the
Th1/Th2 balance in favour of Th2 (T-helper 2) will also
mean suppression of antitumour immunological func-
tions mediated by NK cells and cytotoxic CD8
+
T-lymphocytes.
For optimizing the diet of cancer patients (or other
patients who suffer from protein catabolic conditions)
who often also suffer from the problem that their appe-
tite may be depressed (either because of the disease, or
as a side effect of rough therapy with cytotoxic drugs), it
w i l lo b v i o u s l yb ea na d v a n t a g ef o rt h ed i e t i c i a na n d
nurses to have access to a variety of different foods that
all have a composition that is good for the patients. It
might be easier to encourage the patient to eat as much
nutritious food as he or she needs if the patient can
himself decide whether he prefers fish, poultry meat or
pork for dinner that day, while the dietician knows that
they all have a composition that is good for the patient
(without too much AA and with high Se concentration).
The same will, of course, also be true for all other hos-
pital patients as well as for all geriatric patients in nur-
sing homes, whenever there is a problem with poor
appetite or enhanced protein catabolism.
The importance of Se for cancer patients is supported
by heavy theoretical arguments based on what is known
about the biochemical functions of Se-dependent
enzymes and the importance of Se not only for antioxi-
dant defence and control of eicosanoid biosynthesis, but
also for immunological functions [122,270]. But it is also
consistent with the results of a clinical trial where
patients who had earlier been treated for basal cell or
squamous cell carcinomas of the skin were given 200
microg of Se per day or placebo to see if it could pre-
vent new skin cancer [271]. The patients were treated
for a mean of 4.5 years (SD 2.8 years) and had an aver-
age total follow-up of 6.4 years (SD 2.0 years) [271]. No
effect on the recurrence of skin cancers was found, but
analysis of secondary end points revealed that, compared
with controls, patients treated with Se had a nonsignifi-
cant reduction in all-cause mortality (108 deaths in the
Se group and 129 deaths in the control group [RR; 0.83;
95% CI, 0.63-1.08]) and significant reductions in total
cancer mortality (29 deaths in the Se treatment group
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total cancer incidence (77 cancers in the Se group and
119 in controls [RR, 0.63; 95% CI, 0.47-0.85]), and inci-
dences of lung, colorectal, and prostate cancers [271].
Given the comparatively short duration of this experi-
m e n t ,c o m p a r e dt ow h a ti sk n o w na b o u tt h el a t e n c y
period e.g. for lung cancer among smokers, it is difficult
to explain the observations from this experiment (if
valid) as caused only by a primary prophylactic effect. It
is more plausible to explain it as being in large measure
due to a therapeutic effect on the rate of progression of
cancer that is already established, but still undiagnosed.
But there is no good reason to believe that a therapeutic
effect of high Se intake on the rate of progression of
cancer should be much less in late rather than in very
early stages of the disease.
Is it good prophylactic health policy to use dietary
supplements to compensate for the consequences of low
dietary intake of Se and unnatural fatty acid composition
of poultry and swine meat?
If one wishes to reduce the burden of disease at a popu-
lation level, increasing the Se intake through the ordin-
ary diet may be a better strategy, rather than improving
Se status on a more individual basis by use of Se pills.
One reason for this is that it is far more expensive for
the customer to buy Se or other nutrients in form of
pills rather than getting them through the ordinary diet.
It also depends on the level of education and knowledge
about health-related issues w h e t h e ro rn o tp e o p l ew i l l
buy such dietary supplements that are thought by nutri-
tion experts to be good for their health. Both factors
will favour those individuals and families who have the
best education and most money - which means that the
distribution in form of dietary supplements (rather than
through ordinary foods) of such nutrients (like Se) that
might be deficient in the ordinary diet can not be
expected to be much helpful for those socioeconomic
groups who now have the biggest health problems, e.g.
because of smoking or too much alcohol in combination
with poor diet. However, if the same nutrients could
come through commonly eaten foods such as poultry
meat, pork and eggs, it means that one can reach also
many of those people who either can not afford to buy
much dietary supplement preparates or are not well
enough informed about health questions in general that
they understand why it might be useful to take them.
The same can be said for the long-chain omega-3 fatty
acids EPA and DHA, where intake through ordinary
foods will also be a better strategy for reaching the
entire target population, at the same time as intake
through ordinary foods will be associated with less risk
of EPA and DHA peroxidation during storage, com-
pared with fish oil capsules (since rancidification of
foods is very easily detected by consumers and an
important reason for not eating the food, while the
same may not be the case for fish oil inside a capsule).
Also when EPA and DHA come from animal foods
rather than as purified dietary supplements, they will be
ingested together with antioxidant nutrients that are
important for prevention of peroxidation in vivo (follow-
ing ingestion), such as Se, GSH (plus GSH precursor
amino acids), carnosine and taurine. These nutrients can
because of their antioxidant properties protect against
t i s s u ed a m a g ec a u s e db yi s c h e m i aa n dr e p e r f u s i o n
[154,252,255,272-277] (in which respect they may very
likely interact synergistically with each other, even if
such interactions may still not have been much systema-
tically studied either through animal experiments or
clinical trials), and also against oxidative and nitrative
stress-mediated tissue damage caused by severe infec-
tious diseases, like hypervirulent avian influenza
[90,122,154]. Some of them (if not all?) have also impor-
tant antimutagenic [278], anticarcinogenic [279,280],
and anti-inflammatory [154,281-283] properties in their
own right. They may thus very likely synergize with
many of the protective effects of long-chain omega-3
fatty acids, both in patients suffering from cardiovascu-
lar diseases, in patients suffering from skeletomuscular
diseases leading to ischemic muscle pain and in patients
suffering from chronic non-infectious inflammatory dis-
eases, such as rheumatoid arthritis or Bekhterev’s
disease.
Optimizing the composition of poultry and pork meat is
practically feasible and can be expected to lead to
significant health improvement at a population level
By adding Se-enriched yeast to the chicken or pig feed
concentrate, a meat that contains the same amount of Se
as in fish, or even higher, can be produced [18,266,284].
The fatty acid metabolism in Se-deficient animals has
earlier been shown to result in reduction of the concen-
trations of long-chain fatty acids such as DHA and other
long chain C20 and C22 polyunsaturated fatty acids in
rats [285]. The reason is not known for certain, but there
is strong reason to expect that Se deficiency will lead to
more rapid degradation of long-chain polyunsaturated
fatty acids by lipid peroxidation. In a previous study in
broilers given a relatively high Se intake through the feed
(0.50 mg/kg diet or 0.84 mg/kg diet), the highest Se
intake resulted also in increased concentration of EPA,
DPA and DHA in the broiler meat [18].
It has been shown that by adding rapeseed oil and lin-
seed oil to chicken diets, one can approximately double
the concentration of very long chain fatty acids in meat
when compared to regular chicken thigh meat
[14,18,41]. Thus, broiler meat may give a significant
contribution to the dietary intake of EPA, DPA and
DHA and be close to rival lean fish such as cod in its
content of the very long chain omega-3 fatty acids. Fatty
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better source of these fatty acids. An experimental diet
containing 40 g rapeseed oil and 10 g linseed oil per kg
diet gave a broiler meat having a favorably low ratio
between total omega-6 and omega-3 fatty acids; being
about 2:1 and the ratio between AA and EPA about
3:1 [41]. This ratio, as earlier explained, is important for
several reasons, i.a. since omega-6 and omega-3 fatty
acids compete with each other for binding to enzymes
and incorporation into membrane lipids [68], and
omega-3 fatty acids can also suppress the expression of
inflammatory genes [70,71], whereas omega-6 fatty acids
have an opposite effect [70]. In addition, the ratio
between omega-6 and omega-3 also influences several
processes at the cellular level including cell growth,
multiplication, apoptosis and cell survival [70], that
might potentially be important especially for cancer
patients.
There are, moreover, also recent observations suggest-
ing that a high dietary intake of EPA and DHA can
modulate the energy metabolism of adipocytes (by indu-
cing mitochondrial biogenesis and beta-oxidation in
these cells) in a way that might be useful for combating
overweight and obesity [286]. Thus, it is possible that
optimizing the omega-3/omega-6 fatty acid ratio of ani-
mal foods also might be useful as one of the compo-
nents in a multifactorial strategy to combat the
epidemic of obesity now being one of the world’sm a j o r
public health problems.
Can changes in sulphur amino acid/GSH status modulate
pain sensitivity, mood and appetite regulation by changing
the rates of prostaglandin, dopamine and serotonin
biosynthesis in the central nervous system?
Other observations [287,288] suggest that the GSH con-
centration in the mammalian brain (including the brain
of humans) may be very poorly homeostatically con-
trolled. The affinity of the transport system for GSH is
s ol o w ,a tl e a s ti nt h er a t[ 2 8 7 ] ,t h a tt h er a t eo fG S H
transport across the blood-brain barrier probably must
be strongly dependent on the GSH concentration in
blood plasma. At the same time, it is now very well
documented that the rate-controlling enzymes in the
synthesis of serotonin and dopamine in the brain, viz.
tryptophan hydroxylase and tyrosine hydroxylase, are
sensitive to oxidative and/or nitrative stress [289-291]. It
is therefore possible that GSH depletion in the blood
plasma, happening because the intake of sulphur amino
acids (or other GSH precursor amino acids) is less than
optimal (or because of too much alcohol or infavourable
balance between hormones either enhancing or inhibit-
ing glutathione synthesis in the liver), directly may lead
to depression of serotonin and dopamine biosynthesis in
the brain (because the two rate-controlling enzymes are
both inhibited as a consequence of impairment of the
antioxidative and antinitrative defense systems when
brain GSH is depleted). This might conceivably contri-
bute to enhancement of psychiatric problems like mor-
bid depression and anxiety, enhanced irritability and
poorly controlled aggressive behaviour. It might, more-
over, be speculated that it also could play an important
role in the etiology of disturbances of eating behaviour,
not only when the main problem is hyperphagia leading
to overweight, metabolic syndrome and obesity, but per-
haps also when it is the opposite, viz. anorexia nervosa.
Given the importance of prostaglandin synthesis not
only peripherally, but also inside the central nervous
system for control of pain sensitivity [82], and given also
the importance of GPx and its reducing substrate GSH
for controlling the rate of the COX reactions, as earlier
explained, there may be good reason to ask what is the
effect of changes in the brain GSH concentration on
pain sensibility, as well as on the control of fever. Is it
possible that depletion of GSH in blood plasma could
be one of the main causes of enhanced pain sensibility
in patients that suffer from protein catabolic conditions
with strong enhancement of the rate of cysteine degra-
dation to sulfuric acid - e.g. in patients suffering from
cancer cachexia? And it is possible that improvement of
GSH status could have an antipyretic effect, e.g. in chil-
dren with high fever, comparable perhaps to the effect
of drugs that inhibit prostaglandin synthesis in the cen-
tral nervous system?
These are important arguments why it might be better
from a public health point of view to optimize the com-
position of commonly eaten animal foods rather than
recommending to the whole population or to special
groups of patients (e.g. with cancer) to restrict their con-
sumption of meat. There are, however, still very impor-
tant global ecological reasons to restrict the total
consumption of animal foods, especially in the more
affluent countries. But it is important, if animal foods
shall be substituted with plant protein foods more than
now, that this can happen in a way not leading to dete-
rioration of the quality of the total diet, e.g. because of
reduction of the intake of sulphur amino acids (as may
happen if animal protein is replaced by soybean pro-
ducts or other legume protein with low concentrations
of S amino acids).
Different methods can be used to optimize the fatty acid
composition of animal foods
We believe that the broiler meat in the study referred to
above [41] from a nutritional point of view (for improv-
ing the health of the consumers and reducing the bur-
den for society from expensive, but entirely preventable
diseases) is a much better alternative to regular broiler
meat. We believe also that it is a better alternative, espe-
cially for patients suffering from depression, from alco-
hol abuse, from eating disorders or from infectious
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(such as rheumatoid arthritis, psoriatic arthritis and
Bekhterev’s disease) and other protein catabolic condi-
tions (e.g. cancer cachexia), to supplying the same nutri-
ents in form of dietary supplements (such as Se pills
and fish oil capsules). One important reason for this is
the synergistic interaction not only between long-chain
omega-3 fatty acids and Se, but also between these sub-
stances and GSH not only in relation to prostaglandin
and thromboxane biosynthesis, but also in relation to
other physiological mechanisms relevant for cardiopro-
tection (such as anti-ischemic protection and prevention
of abnormal electrophysiology in cardiomyocytes), for
reducing the rate of cancer progression, and for reduc-
tion of pain and harmful chronic inflammation. But it is
possible that an optimal feed mixture for producing a
specifically tailored “functional food” meat for patients
suffering from cancer or severe chronic inflammatory
diseases (such as rheumatoid arthritis or Bechterev’s dis-
ease) should contain even more linseed oil and less
rapeseed oil, so as to bring the ratio between omega-6
and omega-3 fatty acids in the meat even lower.
It is in principle easy to imagine other methods than
those we have used for optimizing the omega-6/omega-3
fatty acid ratio of poultry meat, pork meat and eggs. An
obvious alternative to adding omega-3-rich plant oils or
seeds to the feed mixtures is to give the animals much
more green leaves than they commonly receive in mod-
ern industrial farming systems. While this may not be
difficult for small-scale farmers practising various forms
of old-fashioned or more modern forms of organic agri-
culture, it might still be premature to have any firm opi-
nion whether or not it might also be practically and
economically feasible for modern industrial-scale farm-
ers, or what might be the best practical methods for the
latter if they wish to do it. Could we use grass-meal
stored under inert gas as part of the feed mixtures given
to poultry or pigs? Or would it be profitable for farmers
to start growing plant species now regarded only as
weeds for use as chicken feed? We are sorry that we can
not for the moment give any good answer to any of
these questions.
We need new and better regulatory standards for the
composition of all types of meat We have ourselves
been working with broilers rather than with pigs mainly
for the simple reason that the broiler is a much cheaper
experimental animal compared with the pig. But there is
no reason to believe that the same principles can not
also be applied to the production of swine meat, or to
the production of meat from other species of birds, such
as turkey, duck, goose or quail. We believe it is also
important to think about the overall fatty acid composi-
tion of the feed during production of ruminant meat,
especially from beef cattle, and that regulatory standards
should be imposed by law, requiring that the omega-6/
omega-3 concentration ratio of meats, offal and eggs
from all species (including both ruminants, monogastric
mammals and birds) should not be much higher than
might be considered natural for the species concerned.
It is also possible that new regulatory standards should
be imposed regarding conditions during storage and
transport both for animal feed products and for meat,
so as to ensure better protection against peroxidation
than now for such more omega-3 fatty acid-rich pro-
ducts that we desire, at the same time as the human
consumers should be much better protected than now
against all such synthetic antioxidants that can have
mutagenic and/or carcinogenic effects in mammals.
Health economy
Meat from chicken and swine can be improved by feed-
ing strategies to contain less AA and more EPA, DHA
and Se. This review shows the potential health benefits
of such meat. But what would be the estimated cost
compared with the economic gain for society as a
whole, in the hypothetical case that the same principles
should be imposed by law for the entire agricultural sec-
tor in countries such as Norway, the United States,
India, Russia or China?
We will not try to answer this question here, as we
feel it goes far beyond our own respective fields of
scientific competence, at the same time as the question
is such a large one that it would probably not be possi-
ble even for a very well qualified health economist and
statistician to answer it in the space of a short article.
We can, however, give a concrete example for illustrat-
ing one small part of the problem: The consumption of
analgesic (painkiller) medications is increasing world-
wide, and in Norway the average person spends annually
about 100 kroner to buy analgesic drugs (Legemiddel-
forbruket.no). The extra cost of producing meat that is
high in Se and also has a low AA concentration and a
favorably low ratio between omega-6 and omega-3 fatty
acids would also be in this same price-range per person
per year. But huge benefits in the health and social bud-
gets from reduction in sick leaves, early retirement
(e.g. because of painful skeletomuscular diseases) and
consumption of hospital and primary health care ser-
vices may be predicted. There would also be important
life-quality benefits not easily measurable for economists
as it might give less pain and suffering, and an improved
all-over health (considering both somatic and psychiatric
morbidity) that many people will consider to represent a
priceless gift. Hopefully, it might also help to reduce the
incidence over the next few decades of chronic diseases,
such as asthma, that are associated with the use of the
analgesic drug acetaminophen, at the same time as it is
also possible that it might help to protect future
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drug-induced mutations.
So if we take only into consideration the problems of
pain and of pain therapy, it is not unreasonable that
there might be a net economic gain for society as a
whole, if all poultry and swine farmers were required by
l a wt om a k eo n l yp r o d u c t sw i t ha nomega-6/omega-3
fatty acid ratio not higher than 2/1 and a Se concentra-
tion similar to what we find in marine fish (which
would be expected to synergize with a reduction of the
AA/(EPA + DPA + DHA) ratio of the meat for checking
the problem of eicosanoid overproduction in many dis-
ease situations). If other diseases (such as cancer and
sudden cardiac death) are also taken into consideration,
it must be expected that the calculated health economic
gain (as based on the best available statistical data)
would be much larger.
We need a better integration of human nutrition science
and human pharmacology, and of agricultural science
with medical science
During those discussions taking place during World
War 2 that preceded the foundation of the FAO, one of
t h em o s ti m p o r t a n th o p e sa n da s p i r a t i o n sw a st h a tt h e
new organization should help to solve important health
problems related to scarcity of food or inadequate nutri-
tional quality of the diet for large groups of people
[292,293], not only in the poor countries (or colonies) in
Africa, Asia and Latin America, but even in some of
those countries that were then among the most affluent
ones in the world. This had its background not only in
t h ew a r - t i m ee x p e r i e n c eo fh o ws e r i o u sc o n s e q u e n c e s
starvation and severe malnutrition can have, and in the
need for economic reconstruction in Europe following
the end of World War 2, but also in what had happened
during the economic crisis of the late 1920s and the
1930s, when farmers in North America were not able to
sell much of the cereal grains that they had produced
(which therefore instead were burnt) at the same time
as large groups of people were undernourished, if not
starving, and infectious diseases including tuberculosis
were taking a heavy toll among undernourished or
poorly nourished people.
The Australian government official and ‘amateur’
economist Frank L. McDougall had advocated a ‘nutri-
tion approach’ to world agriculture and its extension
into ‘economic appeasement’ already during the 1930s,
and was frequently using the slogan ‘to marry health
and agriculture’ [293]. Some people had hoped that the
ideas expressed in this slogan could be realized even at
the organizational level when the United Nations and a
family of related organizations (including WHO, FAO,
WFP, UNICEF and UNESCO) were founded following
the end of World War 2, i.e. that the same organization
might work both with health problems and agriculture
(personal communication from Arne Løchen, who dur-
ing the 1970s was director in the Norwegian National
Nutrition Council/Norwegian FAO Committee). This
did not happen, but the first Director General for the
FAO, Lord Boyd Orr, was by education a medical
doctor.
The problems discussed in this article illustrate how
serious consequences it can have when exactly the
opposite thing happens and health and agriculture
(including the feed industry and food industry sectors)
become totally divorced from each other. The compa-
nies selling feeds to the poultry and pig farmers today
have presumably no idea what their products can do to
the health of human consumers of poultry and pork
meat, while a vast majority of medical practitioners pre-
scribing acetaminophen, NSAIDs or COXIBs to their
patients are probably equally as much ignorant about
the way the fatty acid composition of common animal
foods has changed historically, compared to the natural
composition of the same products (from the same ani-
mal species when living in their natural habitats) and
how this may affect the pain or other important disease
symptoms suffered by their patients.
It may be possible, though, that the most serious pro-
blem here is not the lack of good enough communica-
tion between the community of medical practitioners
and scientists on one side and practitioners and scien-
tists in the agricultural sector on the other, but rather
an absence of good enough integration within medicine
itself, especially as a consequence of poor communica-
tion between human nutrition scientists and human
pharmacologists.
In an essay published in 1948 [294], the British neu-
rologist Walshe draws an analogy between the develop-
ment of medical science and the evolution of the central
nervous system. He quotes the great neurobiologist
Sherrington (1857-1952), who says about the evolution
of the central nervous system in vertebrates that “inte-
gration keeps pace with differentiation”. When as a con-
sequence of evolutionary change sensory organs become
better developed than before, and also those parts of the
central nervous system that process information from
the sensory organ concerned, there will simultaneously
be an expansion of the volume of such parts of the
brain that help to integrate information from that parti-
cular sensory organ with information coming from
other sensory organs. This, says Walshe, is how it also
ought to be in medical science. But it is not how the
situation actually is.
Walshe’s book was published in 1948, when the
volume of medical science (as measured both by the
number of scientists and the total number of new publi-
cations per week) was vastly smaller than today, and
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ical research until then as measured by the total amount
of valid observations available in the bookshelves of uni-
versity libraries (or today also in literature databases).
The total amount of specialized diversity among medical
scientists is also much larger today than it was in 1948,
if we use a definition for diversity analogous to the defi-
nition that palaeontologists and evolutionary biologists
use to quantify biological diversity, i.e. as measured by
the total number of subfields with small groups of scien-
tists that communicate well with each other, but to a
much more limited extent communicate with the rest of
the worldwide community of medical scientists.
It is of little use, when finding a serious problem, to
try to look after individuals or groups of people to be
blamed, unless a correct diagnosis of the problem also
can make it easier to find a solution. This is no less the
case when one is dealing with typical ‘system errors’ or
‘system failure’, as may to a large extent be the case
here, than when individuals (e.g. t h ed i r e c t o ro fac o m -
pany or some prominent politician) are to blame.
A strong plea can, however, be made for much better
integration between agricultural science and human
pharmacology (but also within the medical science com-
munity itself between human pharmacology and human
nutrition science) than we commonly see today. It is
necessary for the pharmacologists, taken as a group, to
learn much more than now about nutrition science, but
it is also important for the human nutrition scientists,
collectively speaking, to learn much more than now
about human pharmacology and the mechanisms of
action of some of the most commonly used drugs.
It is not easy, however, to see how the present situa-
tion may be allowed to continue, if it shall be possible
for the world to mobilize those economic and man-
power resources that we need for simultaneously hand-
ling the serious challenges in the health sector
(in affluent and poor countries alike) and averting unpre-
cedented environmental disaster caused by ourselves.
Conclusion
We believe that making meat high in Se and EPA and
D H Aa n dl o wi nA Ai sag o o ds t r a t e g yf o ri n c r e a s i n g
the dietary intake of Se and very long chain omega-3
fatty acids and for correcting the dietary balance
between omega-6 and omega-3 fatty acids rather than
relying on dietary supplements in form of Se pills and
fish oil capsules, or on fish resources that are already
overexploited and can not cover EPA and DHA require-
ments (for ensuring optimal health) for more than a
fraction of the world’s total population. A reduction of
the dietary level of AA can only be obtained by reduc-
tion of the AA concentration in animal products, or by
drastically reducing the dietary intake of such products
that now contain too much AA.
The combination of inadequate intakes of EPA and
DHA with overconsumption of AA is now one of the
major causes of high rates of cardiovascular death in
many of the ‘old’ industrial countries, and there is rea-
son to fear that some of the countries in Asia with
rapidly growing economies may soon follow because of
the modernization processes affecting much of the ani-
mal food production in those countries as well. At the
same time, it is likely that a high dietary AA/(EPA +
DPA + DHA) ratio also may lead to more rapid devel-
opment of most cancers, especially in such cases where
the tumour cells are expressing COX-2, and to aggrava-
tion of several chronic pain conditions and chronic
inflammatory diseases. AA comes nearly exclusively
from animal foods, and the best strategy for reducing
the average AA intake at a population level is to make it
mandatory for the farmers (and for the feed industry)
that animal products shall have an omega-6/omega-3
fatty acid ratio that must not be higher than what might
be considered natural for the species concerned (when
the animals live in their natural habitats). Since endo-
genous synthesis of AA from LA is also substantial (and
similar to the average intake of AA from the diet), we
believe it may be almost equally important also to
reduce the average LA intake from edible fats and oils,
compared to the situation in several countries today.
Perhaps even more serious than the premature death
of aging individuals from heart disease or cancer are
those health problems that may develop as a conse-
quence of overutilization of mutagenic drugs among
young individuals who suffer from such non-lethal con-
ditions that are nevertheless important as causes of
pain. It is possible that acetaminophen (paracetamol) as
a consequence of the pattern of localization of acetami-
nophen-metabolizing enzymes inside the cells, at least
in the brain, may act mainly as a mitochondrial mutagen
(with much less effect on the DNA molecules in the cell
nucleus). If so, it is possible that acetaminophen may be
relatively unimportant as a contributory cause of cancer,
while it might be very important as a cause of prema-
ture aging of mitochondrial DNA both in the brain and
certain other organs.
It is possible that such mechanisms might help to
explain the epidemiological association that has been
observed between acetaminophen consumption and
asthma. The role of paracetamol as a causative factor in
other diseases has not been equally well studied by epi-
demiologists as in the case of childhood asthma. But
what about degenerative diseases affecting the brain,
such as Alzheimer’s disease - is it possible that acetami-
nophen consumption could have a similar effect there
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where enhanced mitochondrial ROS production in the
brain also might be harmful? And what about pancreatic
beta-cells also expressing the acetaminophen-metaboliz-
ing enzyme CYP2E1 (which at least some of the pan-
creatic beta-cell lines grown in vitro do) [295]? Animal
experiments have suggested that accumulation of muta-
tions in beta-cell mitochondrial DNA could be an
important part of the pathogenetic mechanism in type-2
diabetes [67]. Is it possible that acetaminophen also
c o u l dp l a yar o l ea so n ea m o n g several contributory
causes of type 2 diabetes by enhancing the rate of muta-
genesis in beta-cell mitochondrial DNA? For these ques-
tions, we have still no final answers. But there must be
ample reason, especially when combining all the good
epidemiological studies linking acetaminophen and
asthma with what is already known about the details of
the metabolism of this drug (not only by cytochrome
P450, but also by cyclooxygenases), to be extremely
worried.
Liberalizing the distribution and consumption of a
cheap, but mutagenic pain-killing drug is obviously not
any good alternative to offering good prophylaxis or
therapy for the disease causing the pain, or for normal-
izing the function of hypersensitive pain fibres. Still, this
is exactly what the world is doing today. There might be
more than one reason for this. But the most important
one is probably also here the fragmentation and lack of
integration of medical research knowledge, both when
considering the communication between medical and
agricultural scientists, between different subgroups of
medical scientists and between all the scientists on one
side and the medical practitioners plus the health and
agricultural (plus pollution control) authorities in per-
haps most countries in the world on the other.
A substantial share of the world’s population lives in
such poverty that their consumption of animal foods is
very low. For these people, it must be expected that
endogenous synthesis of long-chain PUFAs from LA and
A L Am u s tb em u c hm o r ei m p o r t a n tt h a nt h ei n t a k eo f
long-chain PUFAs as such from the diet. If the LA/ALA
ratio in the diet is then too high, it must be expected to
have all the same adverse consequences as when the diet-
ary AA/(EPA + DPA + DHA) ratio for more affluent peo-
ple living on an ordinary mixed diet is too high. We
believe therefore that regulatory standards should be
imposed by law, regarding the ALA/LA ratio of edible
fats and oils, especially for ensuring adequate supplies of
DHA for incorporation into the lipids of the brain, retina
and testicles in foetuses and children not only in affluent
families, but also in the poor ones all over the world.
Of all health problems that have been discussed in this
article, none is more serious than the problem of
enhanced mutagenesis in germline cells, and the possibility
that wrong fatty acid composition of the membrane lipids
of male germ cells could be an important cause of
enhanced mitochondrial ROS production enhancing in
turn not only the rate of mitochondrial DNA mutagenesis,
but also the mutation rate in the nuclear DNA of these
cells. In this case, we are dealing with a potential menace
even to the survival of our species. Our descendants can
not afford complacency with the present state of affairs.
Our attitude should not be, as was said in pre-revolution-
ary France: Après nous, le déluge! It is time for the medical
world to wake up, if it shall be possible to save the planet,
including ourselves.
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